Translated Articles from The Oncologist

生物仿制药非格司亭的安全性特征（Zarzio/Zarxio）：III期研究的综合分析
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies
Nadia Harbeck, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Kimberly Blackwell
The Oncologist 2018; 23:403-409; first published on January 9, 2018; doi:10.1634/theoncologist.2017-0348

早期和局部晚期化生性乳腺癌：监测、流行病学和最终结果 (SEER) 2010-2014 中根据受体状态的表现和生存率
Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014
Mary C. Schroeder, Priya Rastogi, Charles E. Geyer Jr., Lance D. Miller, Alexandra Thomas
The Oncologist 2018; 23:481-488; first published on January 12, 2018; doi:10.1634/theoncologist.2017-0398

针对21基因复发评分对ER阳性/HER2阴性乳腺癌患者辅助临床决策的影响进行的首次前瞻性意大利多中心研究
First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
Maria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, Marta Mion, Giampaolo Tortora, Costanza De Rossi, Stefania Gori, Cristina Oliani, Laura Merlini, Felice Pasini, Giorgio Bonciarelli, Gaia Griguolo, Enrico Orvieto, Silvia Michieletto, Tania Saibene, Paola Del Bianco, Gian Luca De Salvo, PierFranco Conte
The Oncologist 2018; 23:297-305; first published on November 13, 2017; doi:10.1634/theoncologist.2017-0322

体质指数和腰围/臀围比值通过雌激素和孕激素受体状态对乳腺癌风险产生的不同影响：一项在华北和华东地区开展的病例对照研究的结果和化学预防的意义
Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case‐Control Study in Northern and Eastern China and Implications for Chemoprevention
Fei Wang, Liyuan Liu, Shude Cui, Fuguo Tian, Zhimin Fan, Cuizhi Geng, Xuchen Cao, Zhenlin Yang, Xiang Wang, Hong Liang, Shu Wang, Hongchuan Jiang, Xuening Duan, Haibo Wang, Guolou Li, Qitang Wang, Jianguo Zhang, Feng Jin, Jinhai Tang, Liang Li, Shiguang Zhu, Wenshu Zuo, Zhongbing Ma, Fei Zhou, Lixiang Yu, Yujuan Xiang, Liang Li, Shuohao Shen, Zhigang Yu
The Oncologist 2017; 22:1431-1443; first published on September 14, 2017; doi:10.1634/theoncologist.2017-0148

将肿瘤特征纳入美国癌症联合委员会乳腺癌分期系统
Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System
Mariana Chavez‐MacGregor, Elizabeth A. Mittendorf, Christina A. Clarke, Daphne Y. Lichtensztajn, Kelly K. Hunt, Sharon H. Giordano
The Oncologist 2017; 22:1292-1300; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0116

每周一次纳米微粒白蛋白结合型紫杉醇新辅助治疗Luminal型早期乳腺癌患者：一项多中心、非随机、II期试验，NABRAX研究（GEICAM/2011-02），包含伴随生物标志物分析的结果
Neoadjuvant Therapy with Weekly Nanoparticle Albumin‐Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011‐02), a Multicenter, Non‐Randomized, Phase II Trial, with a Companion Biomarker Analysis
Miguel Martín, José I. Chacón, Antonio Antón, Arrate Plazaola, Elena García‐Martínez, Miguel A. Seguí, Pedro Sánchez‐Rovira, José Palacios, Lourdes Calvo, Carmen Esteban, Enrique Espinosa, Agusti Barnadas, Norberto Batista, Angel Guerrero, Montserrat Muñoz, Estefania Romio, César Rodríguez‐Martín, Rosalía Caballero, María I. Casas, Federico Rojo, Eva Carrasco, Silvia Antolín
The Oncologist 2017; 22:1301-1308; first published on July 12, 2017; doi:10.1634/theoncologist.2017-0052

HER2阳性和阴性乳腺癌中独特的三级淋巴结构及其与预后的相关性
Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers
Xia Liu, Julia Y.S. Tsang, Thazin Hlaing, Jintao Hu, Yun‐Bi Ni, Siu Ki Chan, Sai Yin Cheung, Gary M. Tse
The Oncologist 2017; 22:1316-1324; first published on July 12, 2017; doi:10.1634/theoncologist.2017-0029

使用同一输液袋输注帕妥珠单抗和曲妥珠单抗后给予长春瑞滨的疗效和安全性：VELVET队列2最终结果
Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results
Michael Andersson, José M. López‐Vega, Thierry Petit, Claudio Zamagni, Valerie Easton, Julia Kamber, Eleonora Restuccia, Edith A. Perez
The Oncologist 2017; 22:1160-1168; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0079

靶向三阴性乳腺癌的分子亚型：理解分子亚型的多样性以在乳腺癌领域获得进展
Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
Clinton Yam, Sendurai A. Mani, Stacy L. Moulder
The Oncologist 2017; 22:1086-1093; first published on May 30, 2017; doi:10.1634/theoncologist.2017-0095

Palbociclib联合氟维司群治疗既往内分泌治疗后疾病进展的绝经前晚期乳腺癌女性：PALOMA-3的结果
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results
Sibylle Loibl, Nicholas C. Turner, Jungsil Ro, Massimo Cristofanilli, Hiroji Iwata, Seock‐Ah Im, Norikazu Masuda, Sherene Loi, Fabrice André, Nadia Harbeck, Sunil Verma, Elizabeth Folkerd, Kathy Puyana Theall, Justin Hoffman, Ke Zhang, Cynthia Huang Bartlett, Mitchell Dowsett
The Oncologist 2017; 22:1028-1038; first published on June 26, 2017; doi:10.1634/theoncologist.2017-0072

细胞周期蛋白依赖性激酶4/6抑制剂治疗乳腺癌的潜在毒性的临床管理以及与该药物相关的药物相互作用：实际考量和建议
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Laura M. Spring, Mark L. Zangardi, Beverly Moy, Aditya Bardia
The Oncologist 2017; 22:1039-1048; first published on July 13, 2017; doi:10.1634/theoncologist.2017-0142

通过关联研究在中国汉族女性中确认了3个与乳腺癌特异性分子亚型相关的易感基因位点
Association Study Confirmed Three Breast Cancer‐Specific Molecular Subtype‐Associated Susceptibility Loci in Chinese Han Women
Yihui Xu, Mengyun Chen, Chenchen Liu, Xiaowei Zhang, Wei Li, Huaidong Cheng, Jun Zhu, Mingjun Zhang, Zhendong Chen, Bo Zhang
The Oncologist 2017; 22:890-894; first published on April 13, 2017; doi:10.1634/theoncologist.2016-0423

HER2阳性转移性乳腺癌患者在既往曲妥珠单抗辅助治疗后接受一线HER2靶向姑息治疗时疗效下降
First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy
Hánah N. Rier, Mark‐David Levin, Joost van Rosmalen, Monique M. E. M. Bos, Jan C. Drooger, Paul de Jong, Johanneke E. A. Portielje, Elisabeth M. P. Elsten, Albert‐Jan Ten Tije, Stefan Sleijfer, Agnes Jager
The Oncologist 2017; 22:901-909; first published on May 22, 2017; doi:10.1634/theoncologist.2016-0448

双重抗HER2治疗用于HER2阳性乳腺癌新辅助治疗的心脏安全性
Cardiac Safety of Dual Anti‐HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2‐Positive Breast Cancer
Anthony F. Yu, Jasmeet C. Singh, Rui Wang, Jennifer E. Liu, Anne Eaton, Kevin C. Oeffinger, Richard M. Steingart, Clifford A. Hudis, Chau T. Dang
The Oncologist 2017; 22:642-647; first published on March 24, 2017; doi:10.1634/theoncologist.2016-0406

内分泌治疗在绝经后雌激素受体阳性转移性乳腺癌治疗中的应用现状
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting
Daniele Generali, Filippo Montemurro, Roberto Bordonaro, Antonino Mafodda, Sante Romito, Andrea Michelotti, Pierluigi Piovano, Maria Teresa Ionta, Claudia Bighin, Donata Sartori, Antonio Frassoldati, Marina Elena Cazzaniga, Ferdinando Riccardi, Franco Testore, Patrizia Vici, Carlo Antonio Barone, Alessio Schirone, Federico Piacentini, Franco Nolè, Annamaria Molino, Luciano Latini, Edda Lucia Simoncini, Fausto Roila, Francesco Cognetti, Francesco Nuzzo, Jennifer Foglietta, Alessandro Marco Minisini, Francesca Goffredo, Giuseppe Portera, Gilda Ascione, Gabriella Mariani
The Oncologist 2017; 22:648-654; first published on April 21, 2017; doi:10.1634/theoncologist.2016-0461

遗传性乳腺癌综合征患者的全身治疗策略
Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes
Amanda Parkes, Banu K. Arun, Jennifer K. Litton
The Oncologist 2017; 22:655-666; first published on May 3, 2017; doi:10.1634/theoncologist.2016-0430

内分泌治疗在绝经后雌激素受体阳性转移性乳腺癌治疗中的应用现状
Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor‐Positive Metastatic Breast Cancer
Virginia G. Kaklamani, William J. Gradishar
The Oncologist 2017; 22:507-517; first published on March 17, 2017; doi:10.1634/theoncologist.2015-0464

SAFE-HEaRt：一项在左心室功能降低的HER2阳性乳腺癌患者中评价HER2靶向治疗的心脏安全性的初步研究 - 原理和设计
SAFE‐HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2‐Positive Breast Cancer and Reduced Left Ventricular Function
Filipa Lynce, Ana Barac, Ming T. Tan, Federico M. Asch, Karen L. Smith, Chau Dang, Claudine Isaacs, Sandra M. Swain
The Oncologist 2017; 22:518-525; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0412

根据中期18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描显示的完全代谢缓解预测乳腺癌患者接受新辅助化疗后的长期生存情况
Complete Metabolic Response on Interim 18F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long‐Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Suyun Chen, Nuhad K. Ibrahim, Yuanqing Yan, Stephen T. Wong, Hui Wang, Franklin C. Wong
The Oncologist 2017; 22:526-534; first published on April 4, 2017; doi:10.1634/theoncologist.2016-0334

治疗中乳腺超声和腋窝超声在不同亚型乳腺癌对新辅助化疗反应方面的预测性能
Performance of Mid‐Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype
Rosalind P. Candelaria, Roland L. Bassett, William Fraser Symmans, Maheshwari Ramineni, Stacy L. Moulder, Henry M. Kuerer, Alastair M. Thompson, Wei Tse Yang
The Oncologist 2017; 22:394-401; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0307

项Ramucirumab或Icrucumab联合卡培他滨治疗局部晚期或转移性乳腺癌既往经治患者的随机、II期研究
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
Linda T. Vahdat, Rachel Layman, Denise A. Yardley, William Gradishar, Mohamad A. Salkeni, Anil Abraham Joy, Agustin A. Garcia, Patrick Ward, James Khatcheressian, Joseph Sparano, Gladys Rodriguez, Shande Tang, Ling Gao, Rita P. Dalal, John Kauh, Kathy Miller
The Oncologist 2017; 22:245-254; first published on February 20, 2017; doi:10.1634/theoncologist.2016-0265

华北和华东地区汉族女性体型大小与乳腺癌之间的相关性
The Association Between Body Size and Breast Cancer in Han Women in Northern and Eastern China
Xin Wang, Liang Li, Jidong Gao, Jiaqi Liu, Mingming Guo, Liyuan Liu, Wenyan Wang, Jie Wang, Zeyu Xing, Zhigang Yu, Xiang Wang
The Oncologist 2016; 21:1362-1368; first published on August 5, 2016; doi:10.1634/theoncologist.2016-0147

Palbociclib联合氟维司群治疗激素受体阳性/HER2阴性晚期转移性乳腺癌女性患者：一项多中心、随机、安慰剂对照III期研究（PALOMA-3）的详细安全性分析
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, Angela M. DeMichele, Sherene Loi, Jungsil Ro, Marco Colleoni, Hiroji Iwata, Nadia Harbeck, Massimo Cristofanilli, Ke Zhang, Alexandra Thiele, Nicholas C. Turner, Hope S. Rugo
The Oncologist 2016; 21:1165-1175; first published on July 1, 2016; doi:10.1634/theoncologist.2016-0097

三阴性乳腺癌的生物学与患者管理
Biology and Management of Patients With Triple-Negative Breast Cancer
Priyanka Sharma
The Oncologist 2016; 21:1050-1062; first published on July 11, 2016; doi:10.1634/theoncologist.2016-0067

基线心功能筛查在早期乳腺癌治疗中的用途评价
Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment
Sandy R. Truong, William T. Barry, Javid J. Moslehi, Emily L. Baker, Erica L. Mayer, Ann H. Partridge
The Oncologist 2016; 21:666-670; first published on April 22, 2016; doi:10.1634/theoncologist.2015-0449

接受芳香化酶抑制剂治疗的绝经后早期乳腺癌女性的患者报告转归与早期停药
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
Kunal C. Kadakia, Claire F. Snyder, Kelley M. Kidwell, Nicholas J. Seewald, David A. Flockhart, Todd C. Skaar, Zereunesay Desta, James M. Rae, Julie L. Otte, Janet S. Carpenter, Anna M. Storniolo, Daniel F. Hayes, Vered Stearns, N. Lynn Henry
The Oncologist 2016; 21:539-546; first published on March 23, 2016; doi:10.1634/theoncologist.2015-0349

接受曲妥珠单抗辅助治疗的早期乳腺癌患者发生充血性心力衰竭的风险：Meta分析
Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis
Hui-Dong Long, Yun-En Lin, Juan-Juan Zhang, Wen-Zhao Zhong, Rui-Nian Zheng
The Oncologist 2016; 21:547-554; first published on March 29, 2016; doi:10.1634/theoncologist.2015-0424

荷兰临床实践中曲妥珠单抗辅助治疗过程中的心脏毒性和心脏监测：荷兰东南部乳腺癌联盟研究
Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium
Shanly C. Seferina, Maaike de Boer, M. Wouter Derksen, Franchette van den Berkmortel, Roel J.W. van Kampen, Agnès J. van de Wouw, Manuela Joore, Petronella G.M. Peer, Adri C. Voogd, Vivianne C.G. Tjan-Heijnen
The Oncologist 2016; 21:555-562; first published on March 23, 2016; doi:10.1634/theoncologist.2015-0230

肥胖与乳腺癌：分子内在联系及潜在临床应用
Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications
Valeria Simone, Morena D’Avenia, Antonella Argentiero, Claudia Felici, Francesca Maria Rizzo, Giovanni De Pergola, Franco Silvestris
The Oncologist 2016; 21:404-417; first published on February 10, 2016; doi:10.1634/theoncologist.2015-0351

紫杉醇联合曲妥珠单抗与帕妥珠单抗治疗HER2阳性转移性乳腺癌患者的心脏安全性
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Anthony F. Yu, Carlos Manrique, Shawn Pun, Jennifer E. Liu, Elton Mara, Martin Fleisher, Sujata Patil, Lee W. Jones, Richard M. Steingart, Clifford A. Hudis, Chau T. Dang
The Oncologist 2016; 21:418-424; first published on March 16, 2016; doi:10.1634/theoncologist.2015-0321

接受骨调节剂治疗的乳腺癌骨转移患者发生骨骼相关事件的危险因素
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents
Ryota Tanaka, Kan Yonemori, Akihiro Hirakawa, Fumie Kinoshita, Naoki Takahashi, Jun Hashimoto, Makoto Kodaira, Harukaze Yamamoto, Mayu Yunokawa, Chikako Shimizu, Manabu Fujimoto, Yasuhiro Fujiwara, Kenji Tamura
The Oncologist 2016; 21:508-513; first published on March 14, 2016; doi:10.1634/theoncologist.2015-0377

肿瘤浸润性淋巴细胞在不同疾病亚型的早期乳腺癌预测和预后中的作用：辅助和新辅助治疗随机临床试验的敏感性分析
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting
Luisa Carbognin, Sara Pilotto, Rolando Nortilli, Matteo Brunelli, Alessia Nottegar, Isabella Sperduti, Diana Giannarelli, Emilio Bria, Giampaolo Tortora
The Oncologist 2016; 21:283-291; first published on February 10, 2016; doi:10.1634/theoncologist.2015-0307

他莫昔芬在乳腺导管内原位癌中的起始治疗
Tamoxifen Initiation After Ductal Carcinoma In Situ
Hazel B. Nichols, Erin J.A. Bowles, Jessica Islam, Lawrence Madziwa, Til Stürmer, Diem-Thy Tran, Diana S.M. Buist
The Oncologist 2016; 21:134-140; first published on January 14, 2016; doi:10.1634/theoncologist.2015-0310

接受含蒽环类方案辅助化疗的乳腺癌患者的心室-动脉偶联
Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy
Graeme J. Koelwyn, Nia C. Lewis, Susan L. Ellard, Lee W. Jones, Jinelle C. Gelinas, J. Douglass Rolf, Bernie Melzer, Samantha M. Thomas, Pamela S. Douglas, Michel G. Khouri, Neil D. Eves
The Oncologist 2016; 21:141-149; first published on January 13, 2016; doi:10.1634/theoncologist.2015-0352

高增殖预测早期乳腺癌新辅助化疗的病理学完全缓解
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
Emilio Alba, Ana Lluch, Nuria Ribelles, Antonio Anton-Torres, Pedro Sanchez-Rovira, Joan Albanell, Lourdes Calvo, Jose Antonio Lopez García-Asenjo, Jose Palacios, Jose Ignacio Chacon, Amparo Ruiz, Juan De la Haba-Rodriguez, Miguel A. Segui-Palmer, Beatriz Cirauqui, Mireia Margeli, Arrate Plazaola, Agusti Barnadas, Maribel Casas, Rosalia Caballero, Eva Carrasco, Federico Rojo
The Oncologist 2016; 21:150-155; first published on January 19, 2016; doi:10.1634/theoncologist.2015-0312

乳腺癌脑转移的多学科治疗诊所：北卡罗来纳大学的经验
A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience
Megan J. McKee, Kevin Keith, Allison M. Deal, Amy L. Garrett, Amy A. Wheless, Rebecca L. Green, Julie M. Benbow, E. Claire Dees, Lisa A. Carey, Matthew G. Ewend, Carey K. Anders, Timothy M. Zagar
The Oncologist 2016; 21:16-20; first published on December 9, 2015; doi:10.1634/theoncologist.2015-0328

在接受新辅助系统治疗联合曲妥珠单抗的HER2过表达局部晚期乳腺癌患者中，高HER2/17号染色体着丝粒探针原位荧光杂交比值可预测病理学完全缓解和生存转归
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
Takahiro Kogawa, Tamer M. Fouad, Diane D. Liu, Jimin Wu, Yu Shen, Hiroko Masuda, Takeo Fujii, Mariana Chavez-MacGregor, Ricardo H. Alvarez, Gabriel N. Hortobágyi, Vicente Valero, Naoto T. Ueno
The Oncologist 2016; 21:21-27; first published on December 9, 2015; doi:10.1634/theoncologist.2015-0101

乳腺神经内分泌癌：现有证据与未来展望
Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives
Alessandro Inno, Giuseppe Bogina, Monica Turazza, Laura Bortesi, Simona Duranti, Alberto Massocco, Giuseppe Zamboni, Giovanni Carbognin, Filippo Alongi, Matteo Salgarello, Stefania Gori
The Oncologist 2016; 21:28-32; first published on December 9, 2015; doi:10.1634/theoncologist.2015-0309

接受二甲双胍治疗的糖尿病乳腺癌患者生存更佳：meta分析
Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis
Hong Xu, Kai Chen, Xiaoyan Jia, Yali Tian, Yun Dai, Dapeng Li, Jing Xie, Min Tao, Yixiang Mao
The Oncologist 2015; 20:1236-1244; first published on October 7, 2015; doi:10.1634/theoncologist.2015-0096

接受曲妥珠单抗联合同期放疗的HER2阳性乳腺癌患者可早期发生左心室舒张功能障碍
Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab
Lu Cao, Gang Cai, Cai Chang, Ai-Yu Miao, Xiao-Li Yu, Zhao-Zhi Yang, Jin-Li Ma, Qian Zhang, Jiong Wu, Xiao-Mao Guo, Jia-Yi ChenThe Oncologist 2015; 20:605-614; first published on May 1, 2015; doi:10.1634/theoncologist.2014-0299

定量分析受体表达以确定乳腺癌原生亚型
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Maggie C.U. Cheang, Miguel Martin, Torsten O. Nielsen, Aleix Prat, David Voduc, Alvaro Rodriguez-Lescure, Amparo Ruiz, Stephen Chia, Lois Shepherd, Manuel Ruiz-Borrego, Lourdes Calvo, Emilio Alba, Eva Carrasco, Rosalia Caballero, Dongsheng Tu, Kathleen I. Pritchard, Mark N. Levine, Vivien H. Bramwell, Joel Parker, Philip S. Bernard, Matthew J. Ellis, Charles M. Perou, Angelo Di Leo, Lisa A. Carey
The Oncologist 2015; 20:474-482; first published on April 23, 2015; doi:10.1634/theoncologist.2014-0372

反相蛋白质阵列用于预测患者出现乳腺癌骨转移低风险
Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer
Naoki Hayashi, Ganiraju C. Manyam, Ana M. Gonzalez-Angulo, Naoki Niikura, Hideko Yamauchi, Seigo Nakamura, Gabriel N. Hortobágyi, Keith A. Baggerly, Naoto T. Ueno
The Oncologist 2014; 19: 909-914

罕见的乳腺癌亚型：组织学、分子学及临床特性
Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities
Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, Pierfranco Conte, Valentina Guarneri
The Oncologist 2014; 19:805-813; first published on June 26, 2014; doi:10.1634/theoncologist.2014-0108

乳腺癌、BRCA突变以及对怀孕和植入前遗传学诊断的态度
Breast Cancer, BRCA Mutations, and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis
Ashley H. Woodson, Kimberly I. Muse, Heather Lin, Michelle Jackson, Danielle N. Mattair, Leslie Schover, Terri Woodard, Laurie McKenzie, Richard L. Theriault, Gabriel N. Hortobágyi, Banu Arun, Susan Peterson, Jessica Profato, Jennifer K Litton
The Oncologist 2014; 19:797-804; first published on June 20, 2014; doi:10.1634/theoncologist.2014-0057

帕妥珠单抗联合曲妥珠单抗和多西他赛对亚洲人表皮生长因子受体-2 阳性转移性乳腺癌患者的安全性：来自 III 期CLEOPATRA研究的结果
Safety Profile of Pertuzumab with Trastuzumab and Docetaxel in Patients from Asia with HER2-Positive Metastatic Breast Cancer: Results from the Phase III Trial CLEOPATRA
Sandra Swain, Young-Hyuck Im, Seock-Ah Im, Valorie Chan, David Miles, Adam Knott, Emma Clark, Graham Ross, Jose Baselga
The Oncologist 2014; 19:693-701; first published on May 28, 2014; doi:10.1634/theoncologist.2014-0033

原发性、转移性以及继发性乳腺癌中激素受体状态的不一致性：生物学差异抑或分类错误
Discordance in Hormone Receptor Status Among Primary, Metastatic, and Second Primary Breast Cancers: Biological Difference or Misclassification
Dominique Sighoko, Juxin Liu, Ningqi Hou, Paul Gustafson, Dezheng Huo
The Oncologist 2014; 19:592-601; first published on May 7, 2014; doi:10.1634/theoncologist.2013-0427

东亚地区中出现的年轻女性乳腺癌患者的独特临床病理学特征与预后：一项基于全国性癌症登记的研究
Distinct Clinicopathological Features and Prognosis of Emerging Young-Female Breast Cancer in an East Asian Country: A Nationwide Cancer Registry-Based Study
Ching-Hung Lin, Po-Ya Chuang, Chun-Ju Chiang, Yen-Shen Lu, Ann-Lii Cheng, Wen-Hung Kuo, Chiun-Sheng Huang, Mei-Shu Lai, San-Lin You, Chao-Hsiun Tang
The Oncologist 2014; 19:583-591; first published on May 7, 2014; doi:10.1634/theoncologist.2014-0047

新一代靶向测序技术在原发性和转移性乳腺癌中检测到大量可作为治疗靶标的序列突变：对临床实践的启示
A Targeted Next Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice
Neil Vasan, Roman Yelensky, Kai Wang, Stacy Moulder, Hannah Dzimitrowicz, Rony Avritscher, Bailiang Wang, Yun Wu, Maureen T. Cronin, Gary Palmer, W Fraser Symmans, Vincent A. Miller, Philip Stephens, Lajos Pusztai
The Oncologist 2014; 19:453-458; first published on April 7, 2014; doi:10.1634/theoncologist.2013-0377

比较吉西他滨联合多西他赛与卡培他滨联合多西他赛 用于转移性乳腺癌的汇总分析
A Pooled Analysis of Gemcitabine Plus Docetaxel versus Capecitabine Plus Docetaxel in Metastatic Breast Cancer
Andrew Seidman, Stephen Chan, Jin Wang, Chao Zhu, Cong Xu, Binghe Xu
The Oncologist 2014; 19:443-452; first published on April 4, 2014; doi:10.1634/theoncologist.2013-0428

艾日布林单药疗法用于年满 70 岁及以上的转移性乳腺癌患者
Eribulin Monotherapy in Patients Aged 70 Years and Older with Metastatic Breast Cancer
Hyman Muss, Javier Cortes, Linda T. Vahdat, Fatima Cardoso, Chris Twelves, Jantien Wanders, Corina E. Dutcus, Jay Yang, Seth Seegobin, Joyce O'Shaughnessy
The Oncologist 2014; 19:318-327; first published on March 28, 2014; doi:10.1634/theoncologist.2013-0282

乳腺癌中功能蛋白组学的意义
Implications of Functional Proteomics in Breast Cancer
Young Kwang Chae, Ana Maria Gonzalez-Angulo
The Oncologist 2014; 19:328-335; first published on March 24, 2014; doi:10.1634/theoncologist.2013-0437

接受曲妥珠单抗治疗的乳腺癌患者输注反应发生率、风险因素和处置的研究
Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab
Lisa M. Thompson, Karen Eckmann, Bonnie L. Boster, Kenneth R. Hess, Laura B. Michaud, Francisco J. Esteva, Gabriel N. Hortobágyi, Chad M. Barnett
The Oncologist 2014; 19:228-234; first published on February 17, 2014; doi:10.1634/theoncologist.2013-0286

人类表皮生长因子受体（HER）家族靶向疗法用于HER2过表达乳腺癌的治疗
Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer
Zeynep Eroglu, Tomoko Tagawa, George Somlo
The Oncologist 2014; 19:135-150; first published on January 16, 2014; doi:10.1634/theoncologist.2013-0283

HER 的故事：揭开晚期乳腺癌 HER-2 靶向治疗的新篇章
HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer
Sunil Verma, Anil A. Joy, Daniel Rayson, Deanna McLeod, Christine Brezden-Masley, Jean-François Boileau, Karen A. Gelmon
The Oncologist 2013; 18:1153-1166; first published on November 8, 2013; doi:10.1634/theoncologist.2013-0217

乳腺癌的多灶性和多中心性与局部区域复发风险
Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence
Siobhan P. Lynch, Xiudong Lei, Limin Hsu, Funda Meric-Bernstam, Thomas A. Buchholz, Hong Zhang, Gabriel N. Hortobágyi, Ana M. Gonzalez-Angulo, Vicente Valero
The Oncologist 2013; 18:1167-1173; first published on October 17, 2013; doi:10.1634/theoncologist.2013-0167

贝伐珠单抗在晚期乳腺癌中的应用：背负众望、大肆宣传以及数以百计的头条报道
Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines
Michael Fralick, Monali Ray, Christina Fung, Christopher M. Booth, Ranjeeta Mallick, Mark J. Clemons
The Oncologist 2013; 18:1174-1179; first published on September 26, 2013; doi:10.1634/theoncologist.2013-0160

DNA 修复基因模式在各乳腺癌分子亚型中的预后和预测意义
DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes
Libero Santarpia, Takayuki Iwamoto, Angelo Di Leo, Naoki Hayashi, Giulia Bottai, Martha Stampfer, Fabrice Andrè, Nicholas C. Turner, W. Fraser Symmans, Gabriel N. Hortobagyi, Lajos Pusztai, Giampaolo Bianchini
The Oncologist 2013; 18:1063-1073; first published on September 26, 2013; doi:10.1634/theoncologist.2013-0163

综述："BRCAness"乳腺肿瘤化疗敏感性的差异
Differential Chemotherapeutic Sensitivity for Breast Tumors with "BRCAness": A Review
Pavani Chalasani, Robert Livingston
The Oncologist 2013; 18:909-916; first published on July 23, 2013; doi:10.1634/theoncologist.2013-0039

早期乳腺癌患者应用阿霉素/环磷酰胺续贯以伊沙匹隆或紫杉醇新辅助治疗和对βIII微管蛋白表达作为预测标记的评价
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer and Evaluation of βIII-Tubulin Expression as a Predictive Marker
Cristina Saura, Ling-Ming Tseng, Stephen Chan, Raju T. Chacko, Mario Campone, Alexy Manikhas, Shona M. Nag, Cynthia G. Leichman, Lokanatha Dasappa, Peter A. Fasching, Fernando Hurtado de Mendoza, W. Fraser Symmans, David Liu, Pralay Mukhopadhyay, Christine Horak, Guan Xing, Lajos Pusztai
The Oncologist 2013; 18:787-794; first published on July 12, 2013; doi:10.1634/theoncologist.2013-0075

早期乳腺癌患者中曲妥珠单抗相关心脏毒性反应：一项队列研究
Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study
Martina Bonifazi, Matteo Franchi, Marta Rossi, Lorenzo Moja, Alberto Zambelli, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, Carlo Zocchetti , Eva Negri
The Oncologist 2013; 18:795-801; first published on July 3, 2013; doi:10.1634/theoncologist.2013-0065

三阴性乳腺癌：三阴性乳腺癌与激素受体阳性/人表皮生长因子受体-2阴性乳腺癌在影像学与病理学表现相关性方面的比较
Triple Negative Breast Cancers: Associations Between Imaging and Pathological Findings for Triple-Negative Tumors Compared With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancers
Martine Boisserie-Lacroix, Gaëtan MacGrogan, Marc Debled, Stéphane Ferron, Maryam Asad-Syed, Pippa McKelvie-Sebileau, Simone Mathoulin-Pélissier, Véronique Brouste, Gabrielle Hurtevent-Labrot
The Oncologist 2013; 18:802-811; first published on July 2, 2013; doi:10.1634/theoncologist.2013-0380

淋巴结阳性和高危淋巴结阴性的人表皮生长因子受体2阳性早期乳腺癌患者应用基于多西他赛和曲妥珠单抗辅助治疗的健康相关生活质量：来自BCIRG 006研究的结果
Health-Related Quality of Life with Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive, and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study
Heather-Jane Au , Wolfgang Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, John Crown, Miguel Martin, Marek Pawlicki, Arlene Chan, John Mackey, John Glaspy, Tamás Pintér, Mei-Ching Liu, Tommy Fornander, Sandeep Sehdev, Jean-Marc Ferrero, Valerie Bée, Maria J. Santana, Dave P. Miller, Deepa Lalla, Dennis J. Slamon, on behalf of the Translational Research In Oncology BCIRG 006 trial investigators
The Oncologist 2013; 18:812-818; first published on June 28, 2013; doi:10.1634/theoncologist.2013-0091

乳腺癌相关中枢神经系统转移的生物学认知和管理的进展
Progress in the Biological Understanding and Management of Breast Cancer-Associated Central Nervous System Metastases
Shaheenah Dawood, Ana M. Gonzalez-Angulo
The Oncologist 2013; 18:675-684; first published on June 5, 2013; doi:10.1634/theoncologist.2012-0438

乳腺癌原发灶与转移灶雌激素受体、孕激素受体和HER2状态的不一致性
Discordance in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis
Elsa Curtit, Virginie Nerich, Laura Mansi, Loic Chaigneau, Laurent Cals, Cristian Villanueva, Fernando Bazan, Philippe Montcuquet, Nathalie Meneveau, Sophie Perrin, Marie-Paule Algros, Xavier Pivot
The Oncologist 2013; 18:667-674; first published on May 30, 2013; doi:10.1634/theoncologist.2012-0350

拉帕替尼、曲妥珠单抗和紫杉醇联合用于人表皮生长因子受体2阳性转移性乳腺癌的一线治疗：一项开放标签的安全性研究
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Francisco Esteva, Sandra X. Franco, Maura K. Hagan, Abenaa Brewster, Robert A. Somer, Will Williams, Allison M. Florance, Simon Turner, Steven Stein, Alejandra Perez
The Oncologist 2013; 18:661-666; first published on May 22, 2013; doi:10.1634/theoncologist.2012-0129

比较化疗用于妊娠期和非妊娠期乳腺癌患者的病例对照研究
Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared with Nonpregnant Patients with Breast Cancer
Jennifer K. Litton, Carla L. Warneke, Karin M. Hahn, Shana L Palla, Henry M. Kuerer, George H. Perkins, Elizabeth A. Mittendorf, Chad Barnett, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Richard L. Theriault
The Oncologist 2013; 18:369-376; first published on April 10, 2013; doi:10.1634/theoncologist.2012-0340

随机、双盲、安慰剂对照III期CLEOPATRA研究中帕妥珠单抗、曲妥珠单抗和多西他赛联合治疗HER2阳性转移性乳腺癌患者的心脏耐受性
Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Sandra M. Swain, Michael S. Ewer, Javier Cortés, Dino Amadori, David Miles, Adam Knott, Emma Clark, Mark C. Benyunes, Graham Ross, José Baselga
The Oncologist 2013; 18:257-264; first published on March 8, 2013; doi:10.1634/theoncologist.2012-0448

一项乳腺癌全球III期临床试验在各地区进行准备所需时间的分析：拉帕替尼和/或曲妥珠单抗优化辅助治疗研究的经验
Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience
Otto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, Kamal S. Saini, José Bines, Sergio D. Simon, Veerle Van Dooren, Gursel Aktan, Kathleen I. Pritchard, Antonio C. Wolff, Ian Smith, Christian Jackisch, Istvan Lang, Michael Untch, Frances Boyle, Binghe Xu, Jose Baselga, Edith A. Perez, Martine Piccart-Gebhart
The Oncologist 2013; 18:134-140; first published on January 28, 2013; doi:10.1634/theoncologist.2012-0342

组织因子作为乳腺癌治疗的新靶点
Tissue Factor as a Novel Target for Treatment of Breast Cancer
Marion Cole, Michael Bromberg
The Oncologist 2013; 18:14-18; first published on January 3, 2013; doi:10.1634/theoncologist.2012-0322

绝经后老年乳腺癌患者的远处复发风险升高：他莫西芬及依西美坦辅助治疗多国研究分析
Elderly Postmenopausal Patients With Breast Cancer Are at Increased Risk for Distant Recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis
Willemien van de Water, Caroline Seynaeve, Esther Bastiaannet, Christos Markopoulos, Steve E. Jones, Daniel Rea, Annette Hasenburg, Hein Putter, Elysée T.M. Hille, Robert Paridaens, Anton J.M. de Craen, Rudi G.J. Westendorp, Cornelis J.H. van de Velde, Gerrit-Jan Liefers
The Oncologist 2013; 18:8-13; first published on December 20, 2012; doi:10.1634/theoncologist.2012-0315

Top of Page

克唑替尼连续治疗期间，克唑替尼相关性复杂性肾囊肿自发性消退
Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment
Samuel J. Klempner, Golnaz Aubin, Atreya Dash, Sai-Hong Ignatius Ou
The Oncologist 2014; 19:1008-1010; first published on August 5, 2014; doi:10.1634/theoncologist.2014-0216 T14-216

Top of Page

多种肿瘤类型中的ALK融合对抗ALK靶向疗法产生反应
LK Fusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy
Jeffrey S. Ross, Siraj M. Ali, Omotayo Fasan, Jared Block, Sumanta Pal, Julia A. Elvin, Alexa B. Schrock, James Suh, Sahar Nozad, Sungeun Kim, Hwa Jeong Lee, Christine E. Sheehan, David M. Jones, Jo‐Anne Vergilio, Shakti Ramkissoon, Eric Severson, Sugganth Daniel, David Fabrizio, Garrett Frampton, Vince A. Miller, Philip J. Stephens, Laurie M. Gay
The Oncologist 2017; 22:1444-1450; first published on October 27, 2017; doi:10.1634/theoncologist.2016-0488

非小细胞肺癌EGFR分子诊断的报告功能的质量评估
Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non‐Small Cell Lung Cancer
Yanxi Han, Rui Zhang, Guigao Lin, Kuo Zhang, Jiehong Xie, Jinming Li
The Oncologist 2017; 22:1325-1332; first published on July 12, 2017; doi:10.1634/theoncologist.2017-0042

靶向深度测序在实体肿瘤患者中的临床应用；靶向深度测序在选定生物标志物临床试验中的有用性
Clinical Application of Targeted Deep Sequencing in Solid‐Cancer Patients and Utility for Biomarker‐Selected Clinical Trials
Seung Tae Kim, Kyoung‐Mee Kim, Nayoung K.D. Kim, Joon Oh Park, Soomin Ahn, Jae‐Won Yun, Kyu‐Tae Kim, Se Hoon Park, Peter J. Park, Hee Cheol Kim, Tae Sung Sohn, Dong Il Choi, Jong Ho Cho, Jin Seok Heo, Wooil Kwon, Hyuk Lee, Byung‐Hoon Min, Sung No Hong, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Woong‐Yang Park, Jeeyun Lee
The Oncologist 2017; 22:1169-1177; first published on July 12, 2017; doi:10.1634/theoncologist.2017-0020

利用靶向新一代测序技术，剖析以福尔马林固定、石蜡包埋的临床结直肠肿瘤样本的癌症基因突变
Profiling Cancer Gene Mutations in Clinical Formalin-Fixed, Paraffin-Embedded Colorectal Tumor Specimens Using Targeted Next-Generation Sequencing
Liangxuan Zhang, Liangjing Chen, Sachin Sah, Gary J. Latham, Rajesh Patel, Qinghua Song, Hartmurt Koeppen, Rachel Tam, Erica Schleifman, Haider Mashhedi, Sreedevi Chalasani, Ling Fu, Teiko Sumiyoshi, Rajiv Raja, William Forrest, Garret M. Hampton, Mark R.Lackner, Priti Hegde, Shidong Jia
The Oncologist 2014; 19:336-343; first published on March 24, 2014; doi:10.1634/theoncologist.2013-0180

新一代测序揭示肝内胆管癌靶向疗法的新路线
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross, Kai Wang, Laurie Gay, Rami Al-Rohil, Janne V. Rand, David M. Jones, Hwa J. Lee, Christine E. Sheehan, Geoff A. Otto, Gary Palmer, Roman Yelensky, Doron Lipson, Deborah Morosini, Matthew Hawryluk, Daniel V. T. Catenacci, Vincent A. Miller, Chaitanya Churi, Siraj Ali, Philip J. Stephens
The Oncologist 2014; 19:235-242; first published on February 21, 2014; doi:10.1634/theoncologist.2013-0352

Hand-Schüller-Christian病及Erdheim-Chester病的并存和差异
Hand-Schüller-Christian Disease and Erdheim-Chester Disease: Coexistence and Discrepancy
Jun Yin, Feng Zhang, Huizhen Zhang, Li Shen, Qing Li, Shundong Hu, Qinghua Tian, Yuqian Bao, Weiping Jia
The Oncologist 2013; 18:19-24; first published on January 8, 2013; doi:10.1634/theoncologist.2012-0234

Top of Page

应用正电子发射断层造影术/计算机断层扫描和生物标记物在转移性结肠癌中的早期治疗反应评价
Positron Emission Tomography/Computed Tomography and Biomarkers for Early Treatment Response Evaluation in Metastatic Colon Cancer
Bodil E. Engelmann, Annika Loft, Andreas Kjær, Hans J. Nielsen, Thomas A. Gerds, Eric v. Benzon, Nils Brünner, Ib J, Christensen, Susanne H. Hansson, Niels H. Holländer, Michael H. Kristensen, Johan Löfgren, Elena Markova, Carsten Sloth, Liselotte Højgaard
The Oncologist 2014; 19:164-172; first published on January 22, 2014; doi:10.1634/theoncologist.2013-0229

Top of Page

降低吸烟相关的癌症发生率与死亡率：医学研究所研讨会总结
Reducing Tobacco-Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop
Erin P. Balogh, Carolyn Dresler, Mark E. Fleury, Ellen R. Gritz, Thomas J. Kean, Matthew L. Myers, Sharyl J. Nass, Brenda Nevidjon, Benjamin A. Toll, Graham W. Warren, Roy S. Herbst
The Oncologist 2014; 19:21-31; first published on December 4, 2013; doi:10.1634/theoncologist.2013-0230

Top of Page

3.9cm肺腺癌的辅助治疗
Adjuvant Therapy for a 3.9-cm Adenocarcinoma of the Lung / Pro / Con
Rebecca Heist, Christopher G. Azzoli
The Oncologist 2013; 18:1258-1261; first published on November 25, 2013; doi:10.1634/theoncologist.2013-0297a

关于放化疗在治疗局部进展期胰腺癌患者中地位的争议
The Controversial Role of Chemoradiation for Patients with Locally Advanced Pancreatic Cancer
Jason E. Faris, Jennifer Y. Wo
The Oncologist 2013; 18:981-985; first published on September 10, 2013; doi:10.1634/theoncologist.2013-0270

Top of Page

氯法拉滨治疗复发性或难治性低度恶性或中度恶性B细胞或T细胞淋巴瘤患者的I期剂量递增研究
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Francine Marie Foss, Terri Parker
The Oncologist 2018; 23:397-e30; first published on February 7, 2018; doi:10.1634/theoncologist.2017-0658

Peutz-Jeghers 综合征患者的化学预防：经验总结
Chemoprevention in Patients with Peutz‐Jeghers Syndrome: Lessons Learned
Justin de Brabander, Ferry A.L.M. Eskens, Susanne E. Korsse, Evelien Dekker, Pieter Dewint, Monique E. van Leerdam, Susanne van Eeden, Heinz‐Josef Klümpen
The Oncologist 2018; 23:399-e33; first published on January 25, 2018; doi:10.1634/theoncologist.2017-0682

在晚期实体瘤患者中进行的Pilaralisib（一种泛I类PI3K抑制剂）片剂剂型I期研究
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Gerald Edelman, Jordi Rodon, Joanne Lager, Christelle Castell, Jason Jiang, Eliezer M. Van Allen, Nikhil Wagle, Neal I. Lindeman, Lynette M. Sholl, Geoffrey I. Shapiro
The Oncologist 2018; 23:401-e38; first published on March 28, 2018; doi:10.1634/theoncologist.2017-0691

帕尼单抗在RAS野生型转移性小肠或肝胰管壶腹部腺癌中的II期研究
Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
Pat Gulhati, Kanwal Raghav, Rachna Shroff, Gauri Varadhachary, Milind Javle, Wei Qiao, Huamin Wang, Jeffrey Morris, Robert Wolff, Michael J. Overman
The Oncologist 2018; 23:277-e26; first published on December 19, 2017; doi:10.1634/theoncologist.2017-0568

Nivolumab在韩国晚期实体瘤患者中的I期药代动力学研究
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
Keun‐Wook Lee, Dae Ho Lee, Jin Hyoung Kang, Joon Oh Park, Se Hyun Kim, Yong Sang Hong, Seung Tae Kim, Do‐Youn Oh, Yung‐Jue Bang
The Oncologist 2018; 23:155-e17; first published on November 20, 2017; doi:10.1634/theoncologist.2017-0528

贝伐珠单抗和伏立诺他治疗世界卫生组织4级恶性胶质母细胞瘤复发患者的II期研究
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
Ashley Ghiaseddin, David Reardon, Woody Massey, Alex Mannerino, Eric S. Lipp, James E. Herndon II, Frances McSherry, Annick Desjardins, Dina Randazzo, Henry S. Friedman, Katherine B. Peters
The Oncologist 2018; 23:157-e21; first published on November 13, 2017; doi:10.1634/theoncologist.2017-0501

奥沙利铂、卡培他滨和塞来昔布联合同步放疗治疗新诊断的可切除直肠癌患者的II期研究
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
Emilio P. Araujo‐Mino, Yehuda Z. Patt, Cristina Murray‐Krezan, Joshua A. Hanson, Pranshu Bansal, Ben J. Liem, Ashwani Rajput, M. Houman Fekrazad, Glenory Heywood, Fa Chyi Lee
The Oncologist 2018; 23:2-e5; first published on November 20, 2017; doi:10.1634/theoncologist.2017-0474

局部晚期胰腺癌患者经新辅助GTX联合或不联合放射治疗的结局和生存期的预测因子
Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy
William H. Sherman, Elizabeth Hecht, David Leung, Kyung Chu
The Oncologist 2018; 23:4-e10; first published on December 6, 2017; doi:10.1634/theoncologist.2017-0208

一项吉西他滨和白蛋白结合型紫杉醇联合apatorsen或安慰剂治疗转移性胰腺癌的随机、双盲、II期试验：RAINIER试验
A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
Andrew H. Ko, Patrick B. Murphy, James D. Peyton, Dianna L. Shipley, Ahmed Al‐Hazzouri, Francisco A. Rodriguez, Mark S. Womack IV, Henry Q. Xiong, David M. Waterhouse, Margaret A. Tempero, Shuangli Guo, Cassie M. Lane, Chris Earwood, Laura M. DeBusk, Johanna C. Bendell
The Oncologist 2017; 22:1427-e129; first published on September 21, 2017; doi:10.1634/theoncologist.2017-0066

Necuparanib联合白蛋白结合型紫杉醇与吉西他滨治疗转移性胰腺癌患者的安全性、药代动力学、药效学和抗肿瘤活性： I期研究结果
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
Eileen M. O'Reilly, James Roach, Paul Miller, Kenneth H. Yu, Catherine Tjan, Molly Rosano, Silva Krause, William Avery, Julie Wolf, Keith Flaherty, Darrell Nix, David P. Ryan
The Oncologist 2017; 22:1429-e139; first published on November 20, 2017; doi:10.1634/theoncologist.2017-0472

5-氟尿嘧啶（5-FU）、奥沙利铂和拉帕替尼联合放疗的新辅助疗法用于局部人表皮生长受体2（HER2）阳性食管胃交界处腺癌患者的导入安全性队列的II期研究
A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2‐Positive Esophagogastric Adenocarcinomas
Gregg Shepard, Edward R. Arrowsmith, Patrick Murphy, John H. Barton, Jr., James D. Peyton, Mark Mainwaring, Laura Blakely, Noel A. Maun, Johanna C. Bendell
The Oncologist 2017; 22:1152-e98; first published on August 1, 2017; doi:10.1634/theoncologist.2017-0186

普瑞巴林用于预防奥沙利铂诱导的痛性神经病变：一项随机、双盲试验
Pregabalin for the Prevention of Oxaliplatin‐Induced Painful Neuropathy: A Randomized, Double‐Blind Trial
Daniel Ciampi de Andrade, Manoel Jacobsen Teixeira, Ricardo Galhardoni, Karine S.L. Ferreira, Paula Braz Mileno, Nathalia Scisci, Alexandra Zandonai, William G.J. Teixeira, Daniel F. Saragiotto, Valquíria Silva, Irina Raicher, Rubens Gisbert Cury, Ricardo Macarenco, Carlos Otto Heise, Mario Wilson Iervolino Brotto, Alberto Andrade de Mello, Marcelo Zini Megale, Luiz Henrique Curti Dourado, Luciana Mendes Bahia, Antonia Lilian Rodrigues, Daniella Parravano, Julia Tizue Fukushima, Jean‐Pascal Lefaucheur, Didier Bouhassira, Evandro Sobroza, Rachel P. Riechelmann, Paulo M. Hoff, PreOx Workgroup, Fernanda Valério da Silva, Thais Chile, Camila S. Dale, Daniela Nebuloni, Luiz Senna, Helena Brentani, Rosana L. Pagano, Ângela M. de Souza
The Oncologist 2017; 22:1154-e105; first published on June 26, 2017; doi:10.1634/theoncologist.2017-0235

一项评价对既往接受过治疗的慢性淋巴细胞白血病患者快速输注Ofatumumab的安全性的II期试验
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
William Donnellan, Jesus G. Berdeja, Diana Shipley, Edward R. Arrowsmith, David Wright, Scott Lunin, Richard Brown, James H. Essell, Ian W. Flinn
The Oncologist 2017; 22:1156-e111; first published on July 7, 2017; doi:10.1634/theoncologist.2017-0236

索拉非尼联合卡培他滨治疗肝细胞癌患者的II期试验：INST 08-20
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
Yehuda Patt, Cristhiam Rojas‐Hernandez, Houman Mohammad Fekrazad, Pranshu Bansal, Fa Chyi Lee
The Oncologist 2017; 22:1156-e111; first published on July 7, 2017; doi:10.1634/theoncologist.2017-0236

一项在携带KRAS突变的既往经治局部晚期或转移性癌症患者中评价Cobimetinib和Duligotuzumab的安全性、耐受性和药代动力学的Ib期剂量递增研究
A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H. Lieu, Manuel Hidalgo, Jordan D. Berlin, Andrew H. Ko, Andres Cervantes, Patricia LoRusso, David E. Gerber, J. Paul Eder, S. Gail Eckhardt, Amy V. Kapp, Amy Tsuhako, Bruce McCall, Andrea Pirzkall, Anne Uyei, Josep Tabernero
The Oncologist 2017; 22:1024-e89; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0175

IV期黑色素瘤患者中伴或不伴射频消融或冷冻消融的内源性热休克蛋白诱导
Endogenous Heat‐Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
Evidio Domingo‐Musibay, James M. Heun, Wendy K. Nevala, Matthew Callstrom, Thomas Atwell, Evanthia Galanis, Lori A. Erickson, Svetomir N. Markovic
The Oncologist 2017; 22:1026-e93; first published on July 5, 2017; doi:10.1634/theoncologist.2017-0060

培美曲塞延时输注联合吉西他滨治疗难治性转移性结直肠癌：临床前依据和II期研究结果
Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
Alessandro Passardi, Francesca Fanini, Livia Turci, Flavia Foca, Paola Rosetti, Silvia Ruscelli, Andrea Casadei Gardini, Martina Valgiusti, Claudio Dazzi, Maurizio Marangolo
The Oncologist 2017; 22:886-e79; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0206

在晚期肾细胞癌受试者中联合使用贝伐珠单抗与伊沙匹隆的一项II期、多中心研究
A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
Mauricio Burotto, Maureen Edgerly, Margarita Velarde, Sanjeeve Balasubramaniam, Harry Drabkin, Juan G. Gormaz, Ciara O'Sullivan, Ravi Madan, Tito Fojo
The Oncologist 2017; 22:888-e84; first published on July 5, 2017; doi:10.1634/theoncologist.2017-0211

晚期肝细胞癌患者中Trebananib联合索拉非尼一线治疗的II期研究
Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, Jean‐Frederic Blanc, Steven Miles, Tom Ganten, Jörg Trojan, Jonathan Cebon, Andre K. Liem, Lara Lipton, Charu Gupta, Benjamin Wu, Michael Bass, Ellen Hollywood, Jennifer Ma, Margaret Bradley, Jason Litten, Leonard B. Saltz
The Oncologist 2017; 22:780-e65; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0058

在铂类药物预处理、晚期头颈部鳞状细胞癌中使用帕尼单抗的多中心II期研究
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
Marco Siano, Francesca Molinari, Vittoria Martin, Nicolas Mach, Martin Früh, Stefania Freguia, Irene Corradino, Michele Ghielmini, Milo Frattini, Vittoria Espeli
The Oncologist 2017; 22:782-e70; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0069

一项依维莫司联合口服泼尼松治疗转移性肾细胞癌患者的II期研究
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
Cristian Lolli, Valentina Gallà, Giuseppe Schepisi, Domenico Barone, Salvatore Luca Burgio, Antonio Maugeri, Bernadette Vertogen, Dino Amadori, Ugo De Giorgi
The Oncologist 2017; 22:784-e74; first published on May 25, 2017; doi:10.1634/theoncologist.2017-0154

Ramucirumab治疗中国晚期实体瘤患者的I期剂量递增研究
Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
Junning Cao, Dongmei Ji, Zhiyu Chen, Weina Shen, Jin Wang, Baoyue Li, Haidong Chi, Amanda Long, Ling Gao, Jin Li
The Oncologist 2017; 22:638-e56; first published on May 2, 2017; doi:10.1634/theoncologist.2017-0137

卡铂联合每周一次白蛋白结合型紫杉醇改良方案治疗非小细胞肺癌老年患者的II期研究：日本北部肺癌研究组1301试验
Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, Shunichi Sugawara, Makoto Maemondo, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Toshiyuki Harada, Hiroshi Watanabe, Taku Nakagawa, Masakazu Ichinose
The Oncologist 2017; 22:640-e59; first published on May 19, 2017; doi:10.1634/theoncologist.2017-0059

一项醋酸阿比特龙与PI3K/mTOR双重抑制剂BEZ235联合治疗转移性去势抵抗性前列腺癌的I期研究
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
Xiao X. Wei, Andrew C. Hsieh, Won Kim, Terence Friedlander, Amy M. Lin, Mirela Louttit, Charles J. Ryan
The Oncologist 2017; 22:503-e43; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0432

索拉非尼（BAY 43-9006）治疗卡波西肉瘤患者的Ib期研究
A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
Thomas S. Uldrick, Priscila H. Gonçalves, Kathleen M. Wyvill, Cody J. Peer, Wendy Bernstein, Karen Aleman, Mark N. Polizzotto, David Venzon, Seth M. Steinberg, Vickie Marshall, Denise Whitby, Richard F. Little, John J. Wright, Michelle A. Rudek, William D. Figg, Robert Yarchoan
The Oncologist 2017; 22:505-e49; first published on March 24, 2017; doi:10.1634/theoncologist.2016-0486

Parsatuzumab（EGFL7抗体）或安慰剂联合FOLFOX和贝伐单抗一线治疗转移性结直肠癌的随机II期试验
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
Rocío García‐Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Jr, Niall Tebbutt, Fadi Braiteh, Guillem Argiles, Zev A. Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert Hurwitz
The Oncologist 2017; 22:375-e30; first published on March 8, 2017; doi:10.1634/theoncologist.2016-0133

Parsatuzumab（EGFL7抗体）或安慰剂联合FOLFOX和贝伐单抗一线治疗转移性结直肠癌的随机II期试验
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
Rocío García‐Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Jr, Niall Tebbutt, Fadi Braiteh, Guillem Argiles, Zev A. Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert Hurwitz
The Oncologist 2017; 22:375-e30; first published on March 8, 2017; doi:10.1634/theoncologist.2016-0133

Pilaralisib（SAR245408，XL147）联合紫杉醇和卡铂治疗实体瘤患者的I期剂量递增研究
Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
Jennifer Wheler, David Mutch, Joanne Lager, Christelle Castell, Li Liu, Jason Jiang, Anne M. Traynor
TThe Oncologist 2017; 22:377-e37; first published on March 8, 2017; doi:10.1634/theoncologist.2016-0257

项Simtuzumab联合FOLFIRI二线治疗转移性KRAS突变结直肠腺癌的II期、随机、双盲、安慰剂对照研究
A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma
J. Randolph Hecht, Al B. Benson III, Dmitry Vyushkov, Yingsi Yang, Johanna Bendell, Udit Verma
The Oncologist 2017; 22:243-e23; first published on February 28, 2017; doi:10.1634/theoncologist.2016-0479

新型紫杉醇口服制剂DHP107治疗晚期实体瘤或胃癌患者的I/IIa期研究
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
Min‐Hee Ryu, Baek‐Yeol Ryoo, Tae Won Kim, Sung Bae Kim, Hyeong‐Seok Lim, Kyun‐Seop Bae, Sook Ryun Park, Yeong‐Woo Jo, Hyun Ju Cho, Yoon‐Koo Kang
The Oncologist 2017; 22:129-e8; first published on February 14, 2017; doi:10.1634/theoncologist.2016-0273

醋酸阿比特龙联合泼尼松治疗转移性前列腺癌黑人男性患者的II期临床试验
Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
Che-Kai Tsao, John Sfakianos, Bobby Liaw, Kiev Gimpel-Tetra, Margaret Kemeny, Linda Bulone, Mohammad Shahin, William Kyu Oh, Matthew David Galsky
The Oncologist 2016; 21:1414-e9; first published on October 14, 2016; doi:10.1634/theoncologist.2016-0026

卡巴他赛与甲氨蝶呤用于曾接受含铂方案治疗的复发性和/或转移性头颈鳞癌患者：随机II期研究
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
Jean-Pascal Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Stéphanie Henry, Lionel D’Hondt, Christophe Lonchay, Stéphane Holbrechts, Petra Boegner, Dany Brohee, Didier Dequanter, Ingrid Louviaux, Brieuc Sautois, Nicolas Whenham, Guy Berchem, Brigitte Vanderschueren, Christel Fontaine, Sandra Schmitz, Aline Gillain, Joelle Schoonjans, Sylvie Rottey
The Oncologist 2016; 21:1416-e17; first published on November 30, 2016; doi:10.1634/theoncologist.2016-0296

较大剂量埃克替尼治疗晚期非小细胞肺癌患者的安全性和药代动力学I期临床试验
A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
Jian Liu, Lihua Wu, Guolan Wu, Xingjiang Hu, Huili Zhou, Junchun Chen, Meixiang Zhu, Wei Xu, Fenlai Tan, Lieming Ding, Yinxiang Wang, Jianzhong Shentu
The Oncologist 2016; 21:1294-1295; first published on October 27, 2016; doi:10.1634/theoncologist.2016-0256

试验药物alisertib联合阿比特龙与泼尼松用于接受阿比特龙治疗后发生进展的转移性去势抵抗性前列腺癌患者的I/II期临床试验
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
Jianqing Lin, Sheel A. Patel, Ashwin R. Sama, Jean H. Hoffman-Censits, Brooke Kennedy, Deborah Kilpatrick, Zhong Ye, Hushan Yang, Zhaomei Mu, Benjamin Leiby, Nancy Lewis, Massimo Cristofanilli, William Kevin Kelly
The Oncologist 2016; 21:1296-1297; first published on October 24, 2016; doi:10.1634/theoncologist.2016-0297

Linsitinib（OSI-906）和拓扑替康治疗复发性小细胞肺癌患者的II期随机研究
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapse Small-Cell Lung Cancer
Alberto A. Chiappori, Gregory A. Otterson, Afshin Dowlati, Anne M. Traynor, Leora Horn, Taofeek K. Owonikoko, Helen J. Ross, Christine L. Hann, Taher Abu Hejleh, Jorge Nieva, Xiuhua Zhao, Michael Schell, Daniel M. Sullivan
The Oncologist 2016; 21:1163-1164; first published on September 30, 2016; doi:10.1634/theoncologist.2016-0220

组蛋白去乙酰化酶抑制剂帕比司他治疗低级别神经内分泌瘤的II期临床试验
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
Ning Jin, Sam J. Lubner, Daniel L. Mulkerin, Saurabh Rajguru, Lakeesha Carmichael, Herb Chen, Kyle D. Holen, Noelle K. LoConte
The Oncologist 2016; 21:785-786; first published on June 3, 2016; doi:10.1634/theoncologist.2016-0060

磷脂酰肌醇3激酶（PI3K）和哺乳动物雷帕霉素靶蛋白（mTOR）双重抑制剂BEZ235治疗晚期肾细胞癌患者的Ib期研究
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo, Ana M. Molina, Yulia Lakhman, Sujata Patil, Kaitlin Woo, John DeLuca, Chung-Han Lee, James J. Hsieh, Darren R. Feldman, Robert J. Motzer, Martin H. Voss
The Oncologist 2016; 21:787-788; first published on June 10, 2016; doi:10.1634/theoncologist.2016-0145

来那度胺和索拉非尼用于晚期肝细胞癌患者的I期研究
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Safi Shahda, Patrick J. Loehrer, Romnee S. Clark, A. John Spittler, Sandra K. Althouse, E. Gabriella Chiorean
The Oncologist 2016; 21:664-665; first published on June 2, 2016; doi:10.1634/theoncologist.2016-0071

催乳素受体拮抗剂LFA102用于转移性乳腺癌和去势抵抗性前列腺癌的I期研究
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
Neeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, Nancy Lewis, Michaela Higgins, Kari Wisinski, Ahmad Awada, Michela Maur, Mark Stein, Andy Hwang, Rebecca Mosher, Ernesto Wasserman, Gang Wu, Hefei Zhang, Renata Zieba, Mohamed Elmeliegy
The Oncologist 2016; 21:535-536; first published on April 18, 2016; doi:10.1634/theoncologist.2015-0502

顺铂/替加氟/尿嘧啶/伊立替康三联方案用于治疗复发性/转移性头颈鳞状细胞癌：I/II期临床研究
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study
San-Chi Chen, Peter Mu-Hsin Chang, Muh-Hwa Yang
The Oncologist 2016; 21:537-538; first published on April 18, 2016; doi:10.1634/theoncologist.2015-0515

II期研究中接受雷莫芦单抗治疗的晚期实体瘤患者的校正QT间期心电图特征
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
Anthony J. Olszanski, David C. Smith, Luis H. Camacho, John Thompson, Suresh S. Ramalingam, R. Donald Harvey, Luis Campos, David Ferry, Shande Tang, Ling Gao, Howard Safran
The Oncologist 2016; 21:402-403; first published on March 16, 2016; doi:10.1634/theoncologist.2015-0467

在大型肿瘤年会投稿的临床试验摘要的最终发表情况评估
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting
Paul R. Massey, Ruibin Wang, Vinay Prasad, Susan E. Bates, Tito Fojo
The Oncologist 2016; 21:261-268; first published on February 17, 2016; doi:10.1634/theoncologist.2015-0516

在仅有肝脏转移的转移性KRAS野生型结直肠癌患者中给予FOLFOXIRI联合帕尼单抗治疗后评价切除术情况的II期研究
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Johanna C. Bendell, Ahmed Zakari, James D. Peyton, Ralph Boccia, Mark Moskowitz, Victor Gian, Andrew Lipman, David Waterhouse, Richard LoCicero, Chris Earwood, Cassie M. Lane, Anthony Meluch
The Oncologist 2016; 21:279-280; first published on February 24, 2016; doi:10.1634/theoncologist.2015-0439

贝伐珠单抗联合替莫唑胺用于一线治疗转移性葡萄膜黑色素瘤患者的II期临床试验
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
Sophie Piperno-Neumann, Alhassane Diallo, Marie-Christine Etienne-Grimaldi, François-Clément Bidard, Manuel Rodrigues, Corine Plancher, Pascale Mariani, Nathalie Cassoux, Didier Decaudin, Bernard Asselain, Vincent Servois
The Oncologist 2016; 21:281-282; first published on February 24, 2016; doi:10.1634/theoncologist.2015-0501

S0502：SWOG伊马替尼联合或不联合贝伐珠单抗用于初治转移性或不可手术切除的胃肠道间质瘤患者III期随机临床研究
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors
Charles D. Blanke, Cathy Rankin, Christopher Corless, Janet F. Eary, Karen Mulder, Scott H. Okuno, Suzanne George, Michael Heinrich
The Oncologist 2015; 20:1353-1354; first published on November 17, 2015; doi:10.1634/theoncologist.2015-0295

替西罗莫司用于去势难治性前列腺癌多西他赛诱导治疗后的维持治疗
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer
Urban Emmenegger, Christopher M. Booth, Scott Berry, Srikala S. Sridhar, Eric Winquist, Nesan Bandali, Annabelle Chow, Christina Lee, Ping Xu, Shan Man, Robert S. Kerbel, Yoo-Joung Ko
The Oncologist 2015; 20:1351-1352; first published on November 5, 2015; doi:10.1634/theoncologist.2015-0220

吉西他滨与多西他赛联合帕唑帕尼用于软组织肉瘤新辅助治疗的Ib/II期研究
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R. Munhoz, Sandra P. D'Angelo, Mrinal M. Gounder, Mary L. Keohan, Ping Chi, Richard D. Carvajal, Samuel Singer, Aimee M. Crago, Jonathan Landa, John H. Healey, Li-Xuan Qin, Meera Hameed, Marietta O. Ezeoke, Arun S. Singh, Mark Agulnik, Bartosz Chmielowski, Jason J. Luke, Brian A. Van Tine, Gary K. Schwartz, William D. Tap, Mark A. Dickson
The Oncologist 2015; 20:1245-1246; first published on October 8, 2015; doi:10.1634/theoncologist.2015-0245

首次应用于人体的概念验证研究：黑色素瘤皮肤转移病灶内注射内皮素受体B拮抗剂BQ788
First-in-Human Proof-of-Concept Study: Intralesional Administration of BQ788, an Endothelin Receptor B Antagonist, to Melanoma Skin Metastases
Jasper Wouters, Robert E. Hunger, Terence Garrod, Benoit Dubuis, Thomas Hunziker, Joost J. van den Oord, Ronit Lahav-le Coutre
The Oncologist 2015; 20:1121-1122; first published on September 1, 2015; doi:10.1634/theoncologist.2015-0139

西妥昔单抗联合多西他赛和顺铂用于不可切除的局部晚期头颈癌患者诱导化疗的随机多中心II期研究
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer
Keun-Wook Lee, Youngil Koh, Sung-Bae Kim, Sang-Won Shin, Jin-Hyoung Kang, Hong-Gyun Wu, Myung-Whun Sung, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Kwang Hyun Kim, Tack-Kyun Kwon, J. Hun Hah, In-Ah Kim, Soon-Hyun Ahn, Dok Hyun Yoon, Sang-Wook Lee, Sang Yoon Kim, Soon Yuhl Nam, Kwang-Yoon Jung, Seung-Kuk Baek, Sook Hee Hong, Se-Hoon Lee, Dae Seog Heo
The Oncologist 2015; 20:1119-1120; first published on August 24, 2015; doi:10.1634/theoncologist.2015-0208

每周一次Oraxol用于转移性或复发性胃癌二线治疗的I期/II期研究
Phase 1/2 study of weekly Oraxol® for the second-line treatment of patients with metastatic or recurrent gastric cancer
Keun-Wook Lee, Kyung Hee Lee, Dae Young Zang, Young Lee Park, Dong Bok Shin, Jin Won Kim, Seock-Ah Im, Sung Ae Koh, Kyung-Sang Yu, Joo-Youn Cho, Jin-A Jung, Yung-Jue Bang
The Oncologist 2015; 20:896-897; first published on June 25, 2015; doi: 10.1634/theoncologist.2015-0202

伊沙匹隆（Ixabepilone）用于转移性宫颈癌的II期临床试验
Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma
Mauricio Burotto, Maureen Edgerly, Marianne Poruchynsky, Margarita Velarde, Julia Wilkerson, Herb Kotz, Susan Bates, Sanjeeve Balasubramaniam, Tito Fojo
The Oncologist 2015; 20:725-726; first published on June 3, 2015; doi:10.1634/theoncologist.2015-0104

贝伐珠单抗、伊立替康和替莫唑胺用于不能切除的胶质母细胞瘤前期治疗的II期临床试验
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma
Katherine B. Peters, Emil Lou, Annick Desjardins, David A. Reardon, Eric S. Lipp, Elizabeth Miller, James E. Herndon II, Frances McSherry, Henry S. Friedman, James J. Vredenburgh
The Oncologist 2015; 20:727-728; first published on May 29, 2015; doi:10.1634/theoncologist.2015-0135

在标准方案治疗失败的转移性结直肠癌患者中比较重组抗肿瘤抗病毒蛋白注射液与安慰剂的II期研究
Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment
Ru Jia, Yan Wang, Xiao-Yang Mao, Shan-Shan Li, Nong Xu, Jian-Ping Xiong, Lin Shen, Li Bai, Wei Liu, Lie-Jun Liu, Fei-Jiao Ge, Yu-Ling Chen, Li Lin, Jian-Ming Xu
The Oncologist 2015; 20:619-620; first published on April 29, 2015; doi:10.1634/theoncologist.2014-0439

硼替佐米和索拉非尼治疗进展期恶性黑色素瘤的I期试验
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Ryan J. Sullivan, Nageatte Ibrahim, Donald P. Lawrence, Julie Aldridge, Anita Giobbie-Hurder, F. Stephen Hodi, Keith T. Flaherty, Christine Conley, James W. Mier, Michael B. Atkins, David F. McDermott
The Oncologist 2015; 20:617-618; first published on May 18, 2015; doi:10.1634/theoncologist.2015-0105

在局部进展期直肠癌患者中开展术前放疗联合卡培他滨、奥沙利铂和贝伐珠单抗同期治疗继以手术和术后5-氟尿嘧啶、亚叶酸、奥沙利铂（FOLFOX）和贝伐珠单抗治疗的II期临床试验：ECOG-ACRIN癌症研究组E3204研究的5年临床结果
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204
Jerome C. Landry, Yang Feng, Roshan S. Prabhu, Steven J. Cohen, Charles A. Staley, Richard Whittington, Elin Ruth Sigurdson, Halla Nimeiri, Udit Verma, Al Bowen Benson
The Oncologist 2015; 20:615-616; first published on April 29, 2015; doi:10.1634/theoncologist.2015-0106

雷莫芦单抗联合紫杉醇在进展期胃腺癌患者中的安全性和药代动力学：Ib期研究
A Phase Ib Study of Safety and Pharmacokinetics of Ramucirumab in Combination With Paclitaxel in Patients With Advanced Gastric Adenocarcinomas
Shinya Ueda, Taroh Satoh, Masahiro Gotoh, Ling Gao, Toshihiko Doi
The Oncologist 2015; 20:493-494; first published on April 17, 2015; doi:10.1634/theoncologist.2014-0440

每周一次白蛋白结合型紫杉醇联合卡铂和同期放疗治疗III期非小细胞肺癌
nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer
Philip Edward Lammers, Bo Lu, Leora Horn, Yu Shyr, Vicki Keedy
The Oncologist 2015; 20:491-492; first published on April 6, 2015; doi:10.1634/theoncologist.2015-0030

索拉非尼与硼替佐米一线治疗转移性或不可切除肾细胞癌的II期研究
Phase II Study of Sorafenib and Bortezomib for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma
Arpit Rao, Richard Lauer
The Oncologist 2015; 20:370-371; first published on March 16, 2015; doi:10.1634/theoncologist.2015-0055

动态对比增强核磁共振成像用于尼达尼布治疗晚期实体瘤的I期研究
Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors
Chooi Peng Lee, N. Jane Taylor, Gerhardt Attard, Simon Pacey, Paul D. Nathan, Johann S. de Bono, Graham Temple, Susan Bell, Martin Stefanic, Peter Stopfer, Adrian Tang, Dow-Mu Koh, David J. Collins, James d'Arcy, Anwar R. Padhani, Martin O. Leach, Ian R. Judson, Gordon J. Rustin
The Oncologist 2015; 20:368-369; first published on March 20, 2015; doi:10.1634/theoncologist.2014-0250

评估双硫仑联合化疗用于转移性非小细胞肺癌治疗的IIb期试验
A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Hovav Nechushtan, Yousef Hamamreh, Salim Nidal, Maya Gotfried, Amichai Baron, Yossi Israeli Shalev, Benjjamin Nisman, Tamar Peretz, Nili Peylan-Ramu
The Oncologist 2015; 20:366-367; first published on March 16, 2015; doi:10.1634/theoncologist.2014-0424

培美曲塞联合吉西他滨与卡铂联合吉西他滨治疗非小细胞肺癌：单中心随机非劣效性II期研究
Pemetrexed and Gemcitabine Versus Carboplatin and Gemcitabine in Non-Small Cell Lung Cancer: A Randomized Noninferiority Phase II Study in One Center
Eva Branden, Gunnar Hillerdal, Karl Kolbeck, Hirsh Koyi
The Oncologist 2015; 20:365; first published on March 2, 2015; doi:10.1634/theoncologist.2014-0181

泛I型PI3K抑制剂Pilaralisib（SAR245408，XL147）联合厄洛替尼治疗实体瘤患者的I期剂量递增试验
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors
Jean-Charles Soria, Patricia LoRusso, Ratislav Bahleda, Joanne Lager, Li Liu, Jason Jiang, Jean-François Martini, Sandrine Macé, Howard Burris
The Oncologist 2015; 20:245-246; first published on February 10, 2015; doi:10.1634/theoncologist.2014-0449

根据观察到的临床缓解情况来调整新辅助化疗重要吗？一项比较以临床反应为指导的治疗与标准治疗用于HER2阴性可手术切除的乳腺癌的随机开放II期研究
Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response-Guided and Standard Treatments in HER2-Negative Operable Breast Cancer
Qian Wang-Lopez, Marie-Ange Mouret-Reynier, Aude-Marie Savoye, Catherine Abrial, Fabrice Kwiatkowski, Christian Garbar, Pascale DuBray-Longeras, Jean-Christophe Eymard, Guillaume Lebouedec, Isabelle Vanpraagh, Frederique Penault-Llorca, Philippe Chollet, Hervé Cure
The Oncologist 2015; 20:243-244; first published on January 30, 2015; doi:10.1634/theoncologist.2014-0400

在既往照射野内复发子宫颈癌患者中开展的顺铂、热疗和拉帕替尼I期研究
Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area
Esther van Meerten, Martine Franckena, Erik Wiemer, Lena van Doorn, Jaco Kraan, Anneke Westermann, Stefan Sleijfer
The Oncologist 2015; 20:241-242; first published on February 6, 2015; doi:10.1634/theoncologist.2014-0365

在原发性乳腺癌女性患者中，给予氟尿嘧啶、表柔比星及环磷酰胺在第1、4天给药，14天为一周期的剂量密集化疗方案，使用非格司亭支持治疗，继以每周一次紫杉醇治疗的II期研究
A Phase II Study of a Dose-Density Regimen With Fluorouracil, Epirubicin, and Cyclophosphamide on Days 1 and 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer
Elisabetta Pietri, Daniele Andreis, Francesca Fabbri, Cecilia Menna, Alessio Schirone, Barbara Kopf, Andrea Rocca, Dino Amadori, Ugo De Giorgi
The Oncologist 2015; 20:239-240; first published on January 30, 2015; doi:10.1634/theoncologist.2014-0326

卡铂联合纳米颗粒白蛋白结合型紫杉醇（Abraxane）每周1次或每3周1次方案治疗广泛期小细胞肺癌患者的随机II期研究
A Randomized Phase II Study of Carboplatin and Two with Weekly or Every 3 Week Nanoparticle Paclitaxel (Abraxane) with in Patients with Extensive Stage Small Cell Lung Cancer
Juneko E Grilley-Olson, Vicki L Keedy, Alan Sandler, Dominic T Moore, Mark A Socinski, Thomas E Stinchcombe
The Oncologist 2015; 20:105-106; first published on January 23, 2015; doi:10.1634/theoncologist.2014-0327

贝伐珠单抗联合放疗和替莫唑胺用于新诊断的多形性胶质母细胞瘤患者
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme
Myra E. van Linde, Joost J.C. Verhoeff, Dirk J. Richel, Wouter R. van Furth, Jaap C. Reijneveld, Henk M.W. Verheul, Lukas J.A. Stalpers
The Oncologist 2015; 20:107-108; first published on January 12, 2015; doi:10.1634/theoncologist.2014-0418

剂量密集非聚乙二醇脂质体多柔比星和多西他赛联合化疗治疗乳腺癌：剂量探索研究
Dose-Dense Nonpegylated Liposomal Doxorubicin and Docetaxel Combination in Breast Cancer: Dose-Finding Study
Enrico Ricevuto, Valentina Cocciolone, Maria Mancini, Katia Cannita, Silvio Romano, Gemma Bruera, Michela Pelliccione, Maria Ilaria Adinolfi, Antonietta Ciccozzi, Alberto Bafile, Maria Penco, Corrado Ficorella
The Oncologist 2015; 20:109-110; first published on January 19, 2015; doi:10.1634/theoncologist.2014-0129

卡培他滨标准或连续给药方案用于转移性乳腺癌的对照研究（GEICAM/2009-05）：随机、非劣效性、II期临床试验的遗传药理学分析
Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis
Miguel Martín, Noelia Martínez, Manuel Ramos, Lourdes Calvo, Ana Lluch, Pilar Zamora, Montserrat Muñoz, Eva Carrasco, Rosalía Caballero, José Ángel García-Sáenz, Eva Guerra, Daniela Caronia, Antonio Casado, Manuel Ruíz-Borrego, Blanca Hernando, José Ignacio Chacón, Julio César De la Torre-Montero, Mª Ángeles Jimeno, Lucía Heras, Rosario Alonso, Juan De la Haba, Guillermo Pita, Manuel Constenla, Anna González Neira
The Oncologist 2015; 20:111-112; first published on January 19, 2015; doi:10.1634/theoncologist.2014-0379

卡培他滨联合同步全脑放疗继以卡培他滨和舒尼替尼治疗乳腺癌脑转移的II期试验
A Phase II Trial of Capecitabine Concomitantly with Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases from Breast Cancer
Polly Niravath, Yee Lu Tham, Tao Wang, Angel Rodriguez, Claudette Foreman, Susan G. Hilsenbeck, Richard Elledge, Mothaffar Rimawi
The Oncologist 2015; 20:13; first published on November 6, 2014; doi:10.1634/theoncologist.2014-0278

长期使用沙利度胺和化疗栓塞术治疗肝细胞癌
Chronic Thalidomide and Chemoembolization for Hepatocellular Carcinoma
Jennifer Wu, Jennifer Ng, Paul J. Christos, Alec S. Goldenberg, Joseph Sparano, Max W. Sung, Howard S. Hochster, Franco M. Muggia
The Oncologist 2014; 19:1229-1230; first published on October 31, 2014; doi:10.1634/theoncologist.2014-0283

评价依非韦伦治疗转移性去势抵抗性前列腺癌有效性和安全性的II期试验
A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer
Nadine Houédé, Marina Pulido, Loic Mourey, Florence Joly, Jean-Marc Ferrero, Carine Bellera, Frank Priou, Caroline Lalet, Audrey Laroche-Clary, Mireille Canal Raffin, François Ichas, Alain Puech, Pierre Vincenzo Piazza
The Oncologist 2014; 19:1227-1228; first published on October 29, 2014; doi:10.1634/theoncologist.2014-0345

S-1单药或联合亚叶酸钙作为吉西他滨难治性晚期胰腺癌的二线治疗：一项随机、开放标签、多中心、II期研究
S-1 monotherapy or in combination with leucovorin as second-line treatment in gemcitabine refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study
Feijiao Ge, Nong Xu, Yuxian Bai, Yi Ba, Yanqiao Zhang, Fei Li, Huayan Xu, Ru Jia, Yan Wang, Li Lin, Jianming Xu
The Oncologist 2014, 19:1133-1134. doi: 10.1634/theoncologist.2014-0223 originally published online October 1, 2014

XELIRI联合贝伐珠单抗用于日本转移性结直肠癌患者二线化疗的I/II期研究（BIX研究）
A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients with Metastatic Colorectal Cancer (BIX Study)
Yasuo Hamamoto, Tatsuro Yamaguchi, Tomohiro Nishina, Kentaro Yamazaki, Takashi Ura, Takako Nakajima, Ayumu Goto, Ken Shimada, Norisuke Nakayama, Junichi Sakamoto, Satoshi Morita, Yasuhide Yamada
The Oncologist 2014, 19:1131-1132. doi: 10.1634/theoncologist.2014-0159 originally published online October 3, 2014

异环磷酰胺、甲氨蝶呤、依托泊苷以及泼尼松龙用于既往未治的I/II期结外鼻型自然杀伤/T细胞淋巴瘤的II期研究：韩国癌症研究组多中心试验
A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I, II Extranodal NK/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group
Tae Min Kim, Dong-Wan Kim, Yoon-Koo Kang, Jooseop Chung, Hong-Suk Song, Hyo Jung Kim, Byung Soo Kim, Jong-Seok Lee, Hawk Kim, Sung Hyun Yang, Young Jin Yuh, Sung Hwa Bae, Myung Soo Hyun, Yoon Kyung Jeon, Chul Woo Kim, Dae Seog Heo
The Oncologist 2014, 19:1129-1130. doi: 10.1634/theoncologist.2014-0305 originally published online October 3, 2014

雌二醇继以依西美坦用于可逆性内分泌治疗耐药的激素受体阳性转移性乳腺癌绝经后女性患者的初步研究
A Pilot Study of Estradiol Followed by Exemestane for Reversing Endocrine Resistance in Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer
Pavani Chalasani, Alison Stopeck, Kathryn Clarke, Robert Livingston
The Oncologist 2014, 19:1127-1128. doi: 10.1634/theoncologist.2014-0306 originally published online September 26, 2014

甲氨蝶呤经脑室-腰椎灌注化疗治疗软脑膜癌病：II期研究
Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a phase II study
Ho-Shin Gwak, Jungnam Joo, Sang-Hoon Shin, Heon Yoo, Ji-Youn Han, Heung Tae Kim, Tak Yun, Jungsil Ro, Jin Soo Lee, Seung Hoon Lee
The Oncologist 2014, 19:1044-1045. doi: 10.1634/theoncologist.2014-0199 originally published online September 10, 2014

经高分辨率磁共振成像选择的中危直肠腺癌患者的术前化疗：GEMCAD 0801 II期多中心临床试验
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by-high resolution magnetic resonance imaging (MRI): the GEMCAD 0801 phase II multicenter trial
Carlos Fernandez-Martos, Gina Brown, Rafael Estevan, Antonieta Salud, Clara Montagut, Joan Maurel, Maria Jose Safont, Jorge Aparicio, Jaime Feliu, Ruth Vera, Vicente Alonso, Javier Gallego, Marta Martin, Miguel Pera, Enrique Sierra, Javier Serra, Salvadora Delgado, Jose V Roig, Jesus Santos, Carles Pericay
The Oncologist 2014, 19:1042-1043. doi: 10.1634/theoncologist.2014-0233 originally published online September 10, 2014

厄洛替尼联合达沙替尼治疗非小细胞肺癌的I/II期研究
A Phase I/II Study Combining Erlotinib and Dasatinib in Non–Small Cell Lung Cancer
Kathryn A Gold, J. Jack Lee, Nusrat Harun, Ximing Tang, Justina Price, Jitesh D Kawedia, Hai T Tran, Jeremy J Erasmus, George R Blumenschein, William N William, Ignacio I Wistuba, Faye M Johnson
The Oncologist 2014, 19:1040-1041.doi: 10.1634/theoncologist.2014-0228 originally published online August 28, 2014

吉西他滨与顺铂联合来那度胺作为转移性尿路上皮癌患者一线治疗的Ib/II期临床试验
Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma
Joaquim Bellmunt, Cristina Suarez, Enrique Gallardo, Jordi Rodon, Francesc Pons, Teresa Bonfill, Marta Beltran, Irene Moya, Susana Galtes, Joan Albanell, Joan Carles
The Oncologist 2014; 19: 917-918

吉西他滨与顺铂联合来那度胺作为转移性尿路上皮癌患者一线治疗的Ib/II期临床试验
Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma
Neeraj Agarwal, Andrea B. Apolo, Che-Kai Tsao, Karen M. Lee, James H. Godbold, Rothschild Soto, Austin Poole, Kiev Gimpel-Tetra, Nancy Lowe, William K. Oh, Matthew D. Galsky
The Oncologist 2014; 19: 915-916

阿法替尼作为三线治疗用于罹患含有EGFR野生型IIIB/IV期非小细胞肺癌韩国患者的II期研究
Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
Myung-Ju Ahn, Sang-We Kim, Byoung-Chul Cho, Jin Seok Ahn, Dae Ho Lee, Jong-Mu Sun, Danmassey, Miyoung Kim, Yang Shi, Keunchil Park
The Oncologist 2014; 19:702-703; first published on May 27, 2014; doi:10.1634/theoncologist.2013-0419

羟氯喹用于转移性胰腺腺癌患者的自噬抑制II期药效动力学研究
Phase II and Pharmacodynamic Study of Autophagy Inhibition using Hydroxychloroquine in Patients with Metastatic Pancreatic Adenocarcinoma
Brian M. Wolpin, Douglas A. Rubinson, Xiaoxu Wang, Jennifer A. Chan, James M. Cleary, Peter C. Enzinger, Charles S. Fuchs, Nadine J. McCleary, Jeffrey A. Meyerhardt, Kimmie Ng, Deborah Schrag, Allison L. Sikora, Beverly A. Spicer, Leah Killion, Harvey Mamon, Alec C. Kimmelman
The Oncologist 2014; 19:637-638; first published on May 12, 2014; doi:10.1634/theoncologist.2014-0086

丝裂霉素C联合大剂量5-氟尿嘧啶与亚叶酸钙作为既往多次治疗过的转移性结直肠癌患者的治疗选择：前瞻性II期试验
Mitomycin C and High-Dose 5-Fluorouracil With Folinic Acid as a Therapeutic Option for Heavily Pretreated Patients With Metastatic Colorectal Cancer: Prospective Phase II Trial
Rafał Stec, Lubomir Bodnar, Marta Smoter, Jan Korniluk, Agata Kuchar, Beata Młot, Cezary Szczylik
The Oncologist 2014; 19:356-357; first published on March 28, 2014; doi:10.1634/theoncologist.2014-0029

替西罗莫司与苔藓抑素1治疗转移性肾细胞癌和软组织肉瘤的I期研究
A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
Elizabeth R. Plimack, Tingting Tan, Yu-Ning Wong, Margaret M. von Mehren, Lois Malizzia, Susan K. Roethke, Samuel Litwin, Tianyu Li, Gary R. Hudes, Naomi B. Haas
The Oncologist 2014; 19:354-355; first published on March 27, 2014; doi:10.1634/theoncologist.2014-0020

比较卡铂联合每周1次紫杉醇与多西他赛单药治疗晚期非小细胞肺癌老年患者的随机化II期试验：日本北部肺癌组0801试验
Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel to Docetaxel Alone in Elderly Patients with Advanced Non-Small-Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801
Makoto Maemondo, Akira Inoue, Shunichi Sugawara, Toshiyuki Harada, Yuji Minegishi, Kazuhiro Usui, Koji Miwa, Naoto Morikawa, Mariko Kambe, Kenji Ube, Kana Watanabe, Osamu Ishimoto, Tomohiro Sakakibara, Akihiko Gemma, Toshihiro Nukiwa
The Oncologist 2014; 19:352-353; first published on March 28, 2014; doi:10.1634/theoncologist.2013-0411

比较卡铂联合每周1次紫杉醇与多西他赛单药治疗晚期非小细胞肺癌老年患者的随机化II期试验：日本北部肺癌组0801试验
Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel to Docetaxel Alone in Elderly Patients with Advanced Non-Small-Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801
Makoto Maemondo, Akira Inoue, Shunichi Sugawara, Toshiyuki Harada, Yuji Minegishi, Kazuhiro Usui, Koji Miwa, Naoto Morikawa, Mariko Kambe, Kenji Ube, Kana Watanabe, Osamu Ishimoto, Tomohiro Sakakibara, Akihiko Gemma, Toshihiro Nukiwa
The Oncologist 2014; 19:352-353; first published on March 28, 2014; doi:10.1634/theoncologist.2013-0411

Ramucirumab联合mFOLFOX-6作为一线治疗用于转移性结直肠癌的安全性与疗效评估的开放标记II期研究
An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined with mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer (mCRC)
Rocio Garcia-Carbonero, Fernando Rivera, Joan Maurel, Jean-Pierre M. Ayoub, Malcolm J. Moore, Andres Cervantes, Timothy R. Asmis, Jonathan D. Schwartz, Federico Nasroulah, Shaila Ballal, Josep Tabernero
The Oncologist 2014; 19:350-351; first published on March 27, 2014; doi:10.1634/theoncologist.2014-0028

博舒替尼联合芳香化酶抑制剂依西美坦：绝经后女性经治局部晚期或转移性激素受体阳性/HER2阴性乳腺癌的II期试验
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
Beverly Moy, Patrick Neven, Fabienne Lebrun, Meritxell Bellet, Binghe Xu, Tomasz Sarosiek, Louis Chow, Paul Goss, Charles Zacharchuk, Eric Leip, Kathleen Turnbull, Nathalie Bardy-Bouxin, Ladan Duvillié, István Láng
The Oncologist 2014; 19:348-349; first published on March 27, 2014; doi:10.1634/theoncologist.2014-0021

博舒替尼联合芳香化酶抑制剂依西美坦：绝经后女性经治局部晚期或转移性激素受体阳性/HER2阴性乳腺癌的II期试验
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
Beverly Moy, Patrick Neven, Fabienne Lebrun, Meritxell Bellet, Binghe Xu, Tomasz Sarosiek, Louis Chow, Paul Goss, Charles Zacharchuk, Eric Leip, Kathleen Turnbull, Nathalie Bardy-Bouxin, Ladan Duvillié, István Láng
The Oncologist 2014; 19:346-347; first published on March 27, 2014; doi:10.1634/theoncologist.2014-0022

索拉非尼联合依维莫司治疗基于分子靶点选择的晚期实体瘤患者的Ib期试验
Phase Ib of Sorafenib In Combination With Everolimus In Patients With Advanced Solid Tumors, Selected On The Base Of Molecular Targets
Francesca Toffalorio, Gianluca Spitaleri, Chiara Catania, Laura Dal Zotto, Cristina Noberasco, Angelo Delmonte, Mariacarmela Santarpia, Fabio Vecchio, Veronica Brunelli, Cristiano Rampinelli, Massimo Barberis, Caterina Fumagalli, Massimo Zucchetti, Monique Zangarini, Tullia Diena, Romano Danesi, Filippo de Braud, Tommaso De Pas
The Oncologist 2014; 19:344-345; first published on March 27, 2014; doi:10.1634/theoncologist.2013-0335

连续输注托泊替康与厄洛替尼：在既往接受过托泊替康治疗的卵巢癌中评估Shed胶原蛋白抗原表位作为浸润标志物的研究
Continuous-Infusion Topotecan and Erlotinib: A Study in Topotecan-Pretreated Ovarian Cancer Assessing Shed Collagen Epitopes as a Marker of Invasiveness
Eiran Warner, Leonard Liebes, Benjamin Levinson, Andrea Downey, Amy Tiersten, Franco Muggia
The Oncologist 2014; 19:250; first published on February 21, 2014; doi:10.1634/theoncologist.2013-0398

紫杉醇联合卡培他滨作为晚期胃癌一线化疗的多中心、II期前瞻性研究
The Multicenter, Phase II, Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma
Jifang Gong, Bing Hu, Xiaotian Zhang, Fengchun Zhang, Jun Zhang, Nong Xu, Qingxia Fan, Yuxian Bai, Shunchang Jiao, Jinwan Wang, Chunmei Bai, Leizhen Zheng, Yingqiang Shi, Yunpeng Liu, Jun Liang, Guoqing Hu, Ying Cheng, Ruihua Xu, Yu Bai, Lin Shen
The Oncologist 2014; 19:173-174; first published on January 23, 2014; doi:10.1634/theoncologist.2013-0137

帕妥珠单抗与厄洛替尼治疗复发非小细胞肺癌患者：使用18F-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描成像的II期研究
Pertuzumab and Erlotinib in Patients with Relapsed Non–Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging
Brett Hughes, Linda Mileshkin, Peter Townley, Barbara Gitlitz, Keith Eaton, Paul Mitchell, Rodney Hicks, Katie Wood, Lucas Amler, Bernard M. Fine, David Loecke, Andrea Pirzkall
The Oncologist 2014; 19:175-176; first published on January 23, 2014; doi:10.1634/theoncologist.2013-0026

术前放疗联合西妥昔单抗用于可切除食管腺癌患者围手术期化疗：一项单中心前瞻性II期试验
Adding Preoperative Radiotherapy Plus Cetuximab to Perioperative Chemotherapy for Resectable Esophageal Adenocarcinoma: A Single-Center Prospective Phase II Trial
Inge Ubink, Pieter van der Sluis, Marguerite Schipper, Onne Reerink, Emile Voest, Inne Borel-Rinkes, Harm Wijrdeman, Frank Vleggaar, Marriete Agterof, Esther Overkleeft, Peter Siersema, Richard van Hillegersberg, M.P. Lolkema
The Oncologist 2014; 19:32-33; first published on December 12, 2013; doi:10.1634/theoncologist.2013-0254

卡陪他宾节拍话治疗晚期肝细胞癌患者：一项II期研究
Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
Giovanni Brandi, Francesco de Rosa, Valentina Agostini, Stefania di Girolamo, Pietro Andreone, Luigi Bolondi, Carla Serra, Claudia Sama, Rita Golfieri, Annagiulia Gramenzi, Alessandro Cucchetti, Antonio Daniele Pinna, Franco Trevisani, Guido Biasco , for the ITALIAN LIVER CANCER (ITA.LI.CA) GROUP
The Oncologist 2013; 18:1256-1257; first published on November 13, 2013; doi:10.1634/theoncologist.2013-0093

乙酰左旋肉碱预防沙戈匹隆诱导的周围神经病变的安全性和疗效的双盲、随机II期研究
A Double-Blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-L-Carnitine in the Prevention of Sagopilone-Induced Peripheral Neuropathy
Mario Campone, Dominique Berton-Rigaud, Florence Joly-Lobbede, Jean-Francois Baurain, Frédéric Rolland, Arnulf Stenzl, Michel Fabbro, Marjan van Dijk, Jörg Pinkert, Thomas Schmelter, Natasja de Bont, Patricia Pautier
The Oncologist 2013; 18:1190-1191; first published on October 8, 2013; doi:10.1634/theoncologist.2013-0061

比较干扰素α-2b与不予治疗作为大剂量治疗和自体干细胞移植后复发淋巴瘤患者巩固治疗的随机研究
A Randomized Study of Interferon α-2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients with Relapsed Lymphoma
André Bosly, Andrew Grigg, Harald Holte, Christian Gisselbrecht, John Radford, Andrea Rossi, Armando Lopez-Guillermo, Marek Trneny, Catherine Sebban, Hans Hagberg, Fernando Leal da Costa, Philippe Colombat, Dominique Bron, Bertrand Coiffier
The Oncologist 2013; 18:1189; first published on October 8, 2013; doi:10.1634/theoncologist.2013-0223

达沙替尼 (BMS-354825) 治疗转移性胰腺腺癌的II期临床试验
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Cheng Ean Chee, Smitha Krishnamurthi, Charles J. Nock, Neal J. Meropol, Joseph Gibbons, PingFu Fu, Joseph Bokar, Lois Teston, Timothy O'Brien, Vinay Gudena, Amy Reese, Mark Bergman, Joel Saltzman, John J. Wright, Afshin Dowlati, Joanna Brell
The Oncologist 2013; 18:1091-1092; first published on September 26, 2013; doi:10.1634/theoncologist.2013-0255

剂量密集FEC方案序贯剂量密集伊沙匹隆作为新辅助治疗用于乳腺癌患者：一项可行性研究
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study
Matteo Clavarezza, Roberto Bordonaro, Bruno Daniele, Gabriella Ferrandina, Sandro Barni, Monica Turazza, Francesca Coati, Andrea De Matteis, Sabino De Placido, Francesco Cognetti, Nina Antonina Olmeo, Francesco Carrozza, Paolo Bruzzi, Lucia Del Mastrol, for the Gruppo Italiano Mammella
The Oncologist 2013; 18:924-925; first published on August 12, 2013; doi:10.1634/theoncologist.2013-0222

重组塔乳铁蛋白（Talactoferrin α）在成人非小细胞肺癌患者中对免疫系统的作用
Effect of Talactoferrin Alfa on the Immune System in Adults With Non-Small Cell Lung Cancer
Ravi A. Madan, Kwong-Yok Tsang, Marijo Bilusic, Matteo Vergati, Diane J. Poole, Caroline Jochems, Jo A. Tucker, Jeffrey Schlom, Giuseppe Giaccone, James L. Gulley
The Oncologist 2013; 18:821-822; first published on July 11, 2013; doi:10.1634/theoncologist.2013-0199

AZD1480: 新型JAK2抑制剂用于治疗实体瘤的I期研究
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Elizabeth R. Plimack, Patricia M. LoRusso, Patricia McCoon, Weifeng Tang, Annetta D. Krebs, Gregory Curt, S. Gail Eckhardt
The Oncologist 2013; 18:819-820; first published on July 11, 2013; doi:10.1634/theoncologist.2013-0198

肿瘤放射治疗组试验RTOG8802、 8903、9506和9706中肌层浸润性膀胱癌的保留膀胱治疗：血管内皮生长因子B过度表达预示远处转移增加和生存期缩短
Bladder Preservation Therapy for Muscle-Invading Bladder Cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular Endothelial Growth Factor B Overexpression Predicts for Increased Distant Metastasis and Shorter Survival
Tim Lautenschlaeger, Asha George, Alexander C. Klimowicz, Jason A. Efstathiou, Chin-Lee Wu, Howard Sandler, William U. Shipley, William J. Tester, Michael P. Hagan, Anthony M. Magliocco, Arnab Chakravarti
The Oncologist 2013; 18:685-686; first published on May 31, 2013; doi:10.1634/theoncologist.2012-0461

局灶性前列腺癌高危患者在前列腺癌根治术后应用多西他赛联合CG1940/CF8711新辅助治疗的II期研究
Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
Jacqueline Vuky, John M. Corman, Christopher Porter, Semra Olgac, Evan Auerbach, Kathryn Dahl
The Oncologist 2013; 18:687-688; first published on June 5, 2013; doi:10.1634/theoncologist.2011-0234

在顽固性转移性结直肠癌患者中进行的Tivozanib (AV-951) 联合Everolimus (RAD001) II期多中心研究
Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas Abrams, Peter C. Enzinger, Nadine J. McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava, Jennifer A. Chan, Wolfram Goessling, Lawrence S. Blaszkowsky, Jeffrey G. Supko, Meaghan Elliot, Kaori Sato, Eileen Regan, Jeffrey A. Meyerhardt, Charles S. Fuchs
The Oncologist 2013; 18:377-378; first published on April 11, 2013; doi:10.1634/theoncologist.2012-0378

一项在晚期肝细胞型肝癌患者中进行的索拉非尼II期随机剂量递增试验
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Lorenza Rimassa, Tiziana Pressiani, Corrado Boni, Carlo Carnaghi, Elena Rota Caremoli, Stefano Fagiuoli, Paolo Foa, Stefania Salvagni, Enrico Cortesi, Maria Chiara Tronconi, Nicola Personeni, Silvia Bozzarelli, Maria Chiara Banzi, Silvia Fanello, Fabio Romano Lutman, Laura Giordano, Armando Santoro
The Oncologist 2013; 18:379-380; first published on April 11, 2013; doi:10.1634/theoncologist.2012-0221

卡培他滨、奥沙利铂和贝伐珠单抗用于治疗转移性食管胃腺癌的II期研究
A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Hope E. Uronis, Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S. David Hsu, Michael A. Morse, Herbert Pang, S. Yousuf Zafar, Paul Conkling, Justin Favaro, Christy C. Arrowood, Stephanie M. Cushman, Kellen L. Meadows, John C. Brady, Andrew B. Nixon, Herbert I. Hurwitz
The Oncologist 2013; 18:271-272; first published on March 13, 2013; doi:10.1634/theoncologist.2012-0404

CF102治疗肝细胞癌的开放、剂量递增I/II期研究
CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
Salomon M. Stemmer, Ofer Benjaminov, Gal Medalia, Noab B. Ciuraru, Michael H. Silverman, Sara Bar-Yehuda, Sari Fishman, Zivit Harpaz, Motti Farbstein, Shira Cohen, Renana Patoka, Barak Singer, William D. Kerns, Pnina Fishman
The Oncologist 2013; 18:25-26; first published on January 8, 2013; doi:10.1634/theoncologist.2012-0211

Top of Page

中国乳腺癌治疗观念和实践的转变
Changing Beliefs and Practices in Women with Breast Cancer in China
Michele A. Gadd
The Oncologist 2015; 20:979-980; first published on August 7, 2015; doi:10.1634/theoncologist.2015-0249

乳腺癌中枢神经系统转移
Central Nervous System Metastasis from Breast Cancer (related to Niravath CTR)
Susan Bates
The Oncologist 2015; 20:3-4; first published on December 26, 2014; doi:10.1634/theoncologist.2014-0469

肝细胞癌治疗药物的研发：温故而知新
Drug Development for Hepatocellular Carcinoma: Knowing the Past Helps to Understand the Future
Stephen L. Chan
The Oncologist November 2014 vol. 19 no. 11 1115-1117. First Published Online September 15, 2014 doi: 10.1634/theoncologist.2014-0304

指南与治疗差异的"阴阳"之说
The Yin-Yang of Guidelines and Disparity
Tony Mok
The Oncologist 2014, 19:1011; doi: 10.1634/theoncologist.2014-0282 originally published online September 15, 2014

低剂量计算机断层扫描用于肺癌筛查
Screening for Lung Cancer With Low-Dose Computerized Tomography
Anthony B. Miller
The Oncologist 2013; 18:897-899; first published on August 5, 2013; doi:10.1634/theoncologist.2013-0159

曲妥珠单抗辅助治疗：时间真的很重要吗？
Adjuvant Trastuzumab: Does Time Really Matter?
Sandra Swain
The Oncologist 2013; 18:490-492; first published on April 26, 2013; doi:10.1634/theoncologist.2013-0094

Top of Page

美国多发性骨髓瘤初治患者中硼替佐米联合美法仑和泼尼松与沙利度胺联合美法仑和泼尼松或来那度胺联合美法仑和泼尼松及来那度胺维持治疗的费用效益比较
The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
Louis P. Garrison, Jr., Si-Tien Wang, Hui Huang, Abbie Ba-Mancini, Hongliang Shi, Kristina Chen, Caroline Korves, Ravinder Dhawan, Andrew Cakana, Helgi van de Velde, Deyanira Corzo, Mei Sheng Duh
The Oncologist 2013; 18:27-36; first published on January 8, 2013; doi:10.1634/theoncologist.2011-0380

多发性骨髓瘤新药疗法与其它疗法的患者负担、医疗花费和资源占用：真实世界支付数据的研究结果比较
Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data
April Teitelbaum, Abbie Ba-Mancini, Hui Huang, Henry J. Henk
The Oncologist 2013; 18:37-45; first published on January 8, 2013; doi:10.1634/theoncologist.2012-0113

Top of Page

立体定向放射治疗在I期小细胞肺癌中的应用
Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
Vivek Verma, Charles B. Simone II, Weining Zhen
The Oncologist 2016; 21:131-133; first published on January 13, 2016; doi:10.1634/theoncologist.2015-0348

FOLFOXIRI联合贝伐珠单抗是否应该成为转移性结直肠癌标准一线治疗？
Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
Ryan D. Nipp, David P. Ryan
The Oncologist 2015; 20:236-238; first published on February 6, 2015; doi:10.1634/theoncologist.2014-0495

The Oncologist二十年历程
Two Decades of The Oncologist
Bruce A. Chabner
The Oncologist 2015; 20:1-2; doi:10.1634/theoncologist.2014-0490

临床试验结果：临床试验集市
Clinical Trial Results: A Clinical Trial Bazaar!
Antonio Tito Fojo, Susan E. Bates
The Oncologist 2014; 19:313-314; first published on March 25, 2014; doi:10.1634/theoncologist.2014-0091

Top of Page

神经内分泌肿瘤老年患者的类癌综合征与诊断后一年内的医疗费用
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients
Chan Shen, Yiyi Chu, Daniel M. Halperin, Arvind Dasari, Shouhao Zhou, Ying Xu, James C. Yao, Ya‐Chen Tina Shih
The Oncologist 2017; 22:1451-1462; first published on June 22, 2017; doi:10.1634/theoncologist.2017-0149

不同起始剂量的索拉非尼对分化型甲状腺癌患者的疗效和耐受性
Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients with Differentiated Thyroid Cancer
Ramona Dadu, Steven G Waguespack, Steven I Sherman, Mimi Hu, Naifa L Busaidy, Camilo Jimenez, Mouhammed A Habra, Anita K Ying, Maria E Cabanillas
The Oncologist 2014; 19:477-482; first published on April 14, 2014; doi:10.1634/theoncologist.2013-0409

靶向生物制剂用于二线治疗晚期甲状腺癌患者的临床有效性
Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer
Taofeek K. Owonikoko, Rajasree P. Chowdry, Zhengjia Chen, Sungjin Kim, Nabil F. Saba, Dong M. Shin, Fadlo R. Khuri
The Oncologist 2013; 18:1262-1269; first published on October 23, 2013; doi:10.1634/theoncologist.2013-0250

甲状腺髓样癌的最新认识和控制方法
Current Understanding and Management of Medullary Thyroid Cancer
Madhuchhanda Roy, Herbert Chen, Rebecca S. Sippel
The Oncologist 2013; 18:1093-1100; first published on September 13, 2013; doi:10.1634/theoncologist.2013-0053

甲状腺淋巴瘤：诊断和最佳处理策略的最新进展
Thyroid Lymphoma: Recent Advances in Diagnosis and Optimal Management Strategies
Siun Walsh, Aoife J. Lowery, Denis Evoy, Enda W. McDermott, Ruth S. Prichard
The Oncologist 2013; 18:994-1003; first published on July 23, 2013; doi:10.1634/theoncologist.2013-0036

Top of Page

改变的催化剂：欧洲癌症患者权利法案
A Catalyst for Change: The European Cancer Patient's Bill of Rights
Mark Lawler, Thierry Le Chevalier, Martin J. Murphy, Jr., Ian Banks, Pierfranco Conte, Francesco De Lorenzo, Françoise Meunier, H.M. Pinedo, Peter Selby, Jean-Pierre Armand, Mariano Barbacid, Michèle Barzach, Jonas Bergh, Gerlind Bode, David A. Cameron, Filippo de Braud, Aimery de Gramont, Volker Diehl, Sarper Diler, Sema Erdem, John M. Fitzpatrick, Jan Geissler, Donal Hollywood, Liselotte Højgaard, Denis Horgan, Jacek Jassem, Peter W. Johnson, Peter Kapitein, Joan Kelly, Sandra Kloezen, Carlo La Vecchia, Bob Löwenberg, Kathy Oliver, Richard Sullivan, Josep Tabernero, Cornelis J. Van de Velde, Nils Wilking, Roger Wilson, Christoph Zielinski, Harald zur Hausen, Patrick G. Johnston
The Oncologist 2014; 19:217-224; first published on February 3, 2014; doi:10.1634/theoncologist.2013-0452

Top of Page

阿法替尼对具有ERBB2（HER2）跨膜结构域G660D和V659E突变的癌症的治疗潜力
Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E
Hiromasa Yamamoto, Shinichi Toyooka, Takashi Ninomiya, Shigemi Matsumoto, Masashi Kanai, Shuta Tomida, Katsuyuki Kiura, Manabu Muto, Ken Suzawa, Patrice Desmeules, Mark G. Kris, Bob T. Li, Marc Ladanyi
The Oncologist 2018; 23:150-154; first published on November 16, 2017; doi:10.1634/theoncologist.2017-0345

ESR1突变的转移性乳腺癌：麻省总医院分子与精准医疗（MAP）肿瘤委员会的临床管理思考
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
Aditya Bardia, John A. Iafrate, Tilak Sundaresan, Jerry Younger, Valentina Nardi
The Oncologist 2016; 21:1035-1040; first published on August 22, 2016; doi:10.1634/theoncologist.2016-0240

Top of Page

¹⁸F-氟脱氧葡萄糖正电子发射断层扫描在晚期肠胰神经内分泌肿瘤诊断算法中的临床价值
Clinical Usefulness of ¹⁸ F‐Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero‐Pancreatic Neuroendocrine Neoplasms
Maria Rinzivillo, Stefano Partelli, Daniela Prosperi, Gabriele Capurso, Patrizia Pizzichini, Elsa Iannicelli, Elettra Merola, Francesca Muffatti, Francesco Scopinaro, Orazio Schillaci, Matteo Salgarello, Massimo Falconi, Gianfranco Delle Fave, Francesco Panzuto
The Oncologist 2018; 23:186-192; first published on November 8, 2017; doi:10.1634/theoncologist.2017-0278

瑞戈非尼与曲氟尿苷/Tipiracil治疗接受标准化疗无效的转移性结直肠癌患者（REGOTAS）的倾向评分分析：一项多中心、观察性研究（日本结直肠癌研究学会
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yusuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Chinatsu Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Masahiko Sugiyama, Yoshito Komatsu, Hiroyuki Okuyama, Eishi Baba, Daisuke Sakai, Tomoki Watanabe, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Yasuhiro Shimada
The Oncologist 2018; 23:7-15; first published on September 11, 2017; doi:10.1634/theoncologist.2017-0275

BRAF V600E转移性结直肠癌的多学科治疗中转移瘤切除术的影响：梅奥诊所的经验
Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience
Benny Johnson, Zhaohui Jin, Mark J. Truty, Rory L. Smoot, David M. Nagorney, Michael L. Kendrick, Benjamin R. Kipp, Axel Grothey
The Oncologist 2018; 23:128-134; first published on September 13, 2017; doi:10.1634/theoncologist.2017-0230

靶向药物治疗转移性结直肠癌的顺序和组合策略的全面回顾
A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer
Kristen K. Ciombor, Tanios Bekaii‐Saab
The Oncologist 2018; 23:25-34; first published on October 11, 2017; doi:10.1634/theoncologist.2017-0203

接受至少三线全身化疗的晚期胃癌患者转归研究
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone, Mario Scartozzi, Eufemia Stefania Lutrino, Davide Melisi, Lorenzo Antonuzzo, Antonio Pellegrino, Laura Ferrari, Roberto Bordonaro, Caterina Vivaldi, Lorenzo Gerratana, Silvia Bozzarelli, Roberto Filippi, Domenico Bilancia, Marco Russano, Giuseppe Aprile
The Oncologist 2017; 22:1463-1469; first published on August 31, 2017; doi:10.1634/theoncologist.2017-0158

胃肠癌中TERT启动子甲基化：一种潜在的粪便标志物
TERT Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker
Li Liu, Cheng Liu, Omid Fotouhi, Yidong Fan, Kun Wang, Chuanyou Xia, Benkang Shi, Guangyong Zhang, Kexin Wang, Feng Kong, Catharina Larsson, Sanyuan Hu, Dawei Xu
The Oncologist 2017; 22:1178-1188; first published on July 28, 2017; doi:10.1634/theoncologist.2017-0064

BRCA相关性胆管癌的总生存期和临床特征：一项多中心回顾性研究
Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Talia Golan, Maria Raitses‐Gurevich, Robin K. Kelley, Andrea G. Bocobo, Ayelet Borgida, Rachna T. Shroff, Spring Holter, Steven Gallinger, Daniel H. Ahn, Dan Aderka, Jain Apurva, Tanois Bekaii‐Saab, Eitan Friedman, Milind Javle
The Oncologist 2017; 22:804-810; first published on May 9, 2017; doi:10.1634/theoncologist.2016-0415

标准新辅助放化疗无效的局部晚期直肠癌患者接受全身化疗挽救治疗
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy
Francesco Sclafani, Gina Brown, David Cunningham, Sheela Rao, Paris Tekkis, Diana Tait, Federica Morano, Chiara Baratelli, Eleftheria Kalaitzaki, Shahnawaz Rasheed, David Watkins, Naureen Starling, Andrew Wotherspoon, Ian Chau
The Oncologist 2017; 22:728-736; first published on May 5, 2017; doi:10.1634/theoncologist.2016-0396

项FOLFOX +贝伐珠单抗联合或不联合MET抑制剂Onartuzumab一线治疗转移性结直肠癌患者的II期、随机试验（GO27827)
A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Johanna C. Bendell, Howard Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel Catenacci, Jessie J. Hsu, Stephen P. Hack, David S. Shames, See‐Chun Phan, Hartmut Koeppen, Allen L. Cohn
The Oncologist 2017; 22:264-271; first published on February 16, 2017; doi:10.1634/theoncologist.2016-0223

KRAS突变阴性胰腺导管腺癌中的致癌性ALK融合和RRAS突变
An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation‐Negative Pancreatic Ductal Adenocarcinoma
Yoko Shimada, Takashi Kohno, Hideki Ueno, Yoshinori Ino, Hideyuki Hayashi, Takashi Nakaoku, Yasunari Sakamoto, Shunsuke Kondo, Chigusa Morizane, Kazuaki Shimada, Takuji Okusaka, Nobuyoshi Hiraoka
The Oncologist 2017; 22:158-164; first published on February 6, 2017; doi:10.1634/theoncologist.2016-0194

胃肠胰高分化3级神经内分泌瘤：综述与立场声明
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
Romain Coriat, Thomas Walter, Benoit Terris, Anne Couvelard, Philippe Ruszniewski
The Oncologist 2016; 21:1191-1199; first published on July 8, 2016; doi:10.1634/theoncologist.2015-0476

错配修复缺陷与对免疫检查点阻断治疗的反应
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Valerie Lee, Adrian Murphy, Dung T. Le, Luis A. Diaz, Jr.
The Oncologist 2016; 21:1200-1211; first published on July 13, 2016; doi:10.1634/theoncologist.2016-0046

FOLFOX联合或不联合MET抑制剂onartuzumab治疗晚期胃和胃食道结合部腺癌的II期随机临床研究
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
Manish A. Shah, Jae-Yong Cho, Iain B. Tan, Niall C. Tebbutt, Chia-Jui Yen, Alice Kang, David S. Shames, Lilian Bu, Yoon-Koo Kang
The Oncologist 2016; 21:1085-1090; first published on July 8, 2016; doi:10.1634/theoncologist.2016-0038

RAS和BRAF野生型转移性结直肠癌患者的原发肿瘤病灶部位与抗表皮生长因子受体单克隆抗体治疗的获益
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Roberto Moretto, Chiara Cremolini, Daniele Rossini, Filippo Pietrantonio, Francesca Battaglin, Alessia Mennitto, Francesca Bergamo, Fotios Loupakis, Federica Marmorino, Rosa Berenato, Valentina Angela Marsico, Marta Caporale, Carlotta Antoniotti, Gianluca Masi, Lisa Salvatore, Beatrice Borelli, Gabriella Fontanini, Sara Lonardi, Filippo De Braud, Alfredo Falcone
The Oncologist 2016; 21:988-994; first published on July 5, 2016; doi:10.1634/theoncologist.2016-0084

妊娠期结直肠癌的治疗：细胞毒化疗与靶向治疗的挑战
The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges
Jane E. Rogers, Arvind Dasari, Cathy Eng
The Oncologist 2016; 21:563-570; first published on March 21, 2016; doi:10.1634/theoncologist.2015-0362

结直肠癌错配修复状态对辅助化疗治疗决策的影响：基于人群的澳大利亚多中心研究
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study
Emily Y. He, Nicholas J. Hawkins, Gabriel Mak, Felicia Roncolato, David Goldstein, Winston Liauw, Philip Clingan, Melvin Chin, Robyn L. Ward
The Oncologist 2016; 21:618-625; first published on March 23, 2016; doi:10.1634/theoncologist.2015-0530

结直肠癌幸存者健康相关生活质量的备选预测因素：系统综述
Candidate Predictors of Health-Related Quality of Life of Colorectal Cancer Survivors: A Systematic Review
Martijn J.L. Bours, Bernadette W.A. van der Linden, Renate M. Winkels, Fränzel J. van Duijnhoven, Floortje Mols, Eline H. van Roekel, Ellen Kampman, Sandra Beijer, Matty P. Weijenberg
The Oncologist 2016; 21:433-452; first published on February 24, 2016; doi:10.1634/theoncologist.2015-0258

奥曲肽LAR剂量与晚期神经内分泌肿瘤老年患者的生存
Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors
Chan Shen, Ying Xu, Arvind Dasari, Ya-Chen Tina Shih, James C. Yao
The Oncologist 2016; 21:308-313; first published on February 24, 2016; doi:10.1634/theoncologist.2015-0381

当前对临界可切除胰腺癌和不可切除的局部进展期胰腺癌的管理
Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer
Walid L. Shaib, Andrew Ip, Kenneth Cardona, Olatunji B. Alese, Shishir K. Maithel, David Kooby, Jerome Landry, Bassel F. El-Rayes
The Oncologist 2016; 21:178-187; first published on February 1, 2016; doi:10.1634/theoncologist.2015-0316

家族性胃癌
Familial Gastric Cancers
Namrata Setia, Jeffrey W. Clark, Dan G. Duda, Theodore S. Hong, Eunice L. Kwak, John T. Mullen, Gregory Y. Lauwers
The Oncologist 2015; 20:1365-1377; first published on September 30, 2015; doi:10.1634/theoncologist.2015-0205

消化道癌中的长链非编码核糖核酸：功能、机制和潜在生物 标记物
Long Non-Coding RNA in Digestive Tract Cancer: Function, Mechanism and Potential Biomarker
Bo-Sheng Li, Shuo Zeng, Yu-Feng Xiao, Bo Tang, Chang-Jiang Hu, Rei Xie, Shi-Ming Yang
The Oncologist 2015; 20:898-906; first published on July 8, 2015; doi: 10.1634/theoncologist.2014-0475

对进展期胃癌病例进行前瞻性综合性基因组分析可提示常见临床相关基因变异和靶向治疗的新路径
Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies
Siraj M. Ali, Eric M. Sanford, Samuel J. Klempner, Douglas A. Rubinson, Kai Wang, Norma A. Palma, Juliann Chmielecki, Roman Yelensky, Gary A. Palmer, Deborah Morosini, Doron Lipson, Daniel V. Catenacci, Fadi Braiteh, Rachel Erlich, Philip J. Stephens, Jeffrey S. Ross, Sai-Hong Ignatius Ou, Vincent A. Miller
The Oncologist 2015; 20:499-507; first published on April 16, 2015; doi:10.1634/theoncologist.2014-0378

局部晚期胃食管交界处肿瘤：治疗中的困境
Locally Advanced Gastroesophageal Junction Tumor: A Treatment Dilemma
Richard Kim, Noman Ashraf, Sarah Hoffe
The Oncologist 2015; 20:134-142; first published on January 5, 2015; doi:10.1634/theoncologist.2014-0377

2 型糖尿病与接受结肠癌根治手术的华裔亚洲患者死亡率升高相关
Type 2 Diabetes Mellitus Is Associated With Increased Mortality in Chinese Patients Receiving Curative Surgery for Colon Cancer
Kuo-Hsing Chen, Yu-Yun Shao, Zhong-Zhe Lin, Yi-Chun Yeh, Wen-Yi Shau, Raymond Nienchen Kuo, Ho-Min Chen, Chiu-Ling Lai, Kun-Huei Yeh, Ann-Lii Cheng, Mei-Shu Lai
The Oncologist 2014; 19: 951-958.

晚期胰腺癌：生物治疗时代孕育新方法
Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy
Joanne W. Chiu, Hilda Wong, Roland Leung, Roberta Pang, Tan-To Cheung, Sheung-Tat Fan, Ronnie Poon, Thomas Yau
The Oncologist 2014; 19: 937-950.

在神经内分泌肿瘤患者中使用高于标准剂量奥曲肽 LAR 控制类癌综合征症状的临床获益：多中心回溯性病历研究
Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study
Jonathan R. Strosberg, Al B. Benson, Lynn Huynh, Mei Sheng Duh, Jamie Goldman, Vaibhav Sahai, Alfred W. Rademaker, Matthew H. Kulke
The Oncologist 2014; 19: 930-936.

曲妥珠单抗治疗胃癌研究中的生存质量探讨
Quality of Life in the Trastuzumab for Gastric Cancer (ToGA) Trial
Taroh Satoh, Yung-Jue Bang, Evgeny A Gotovkin, Yasuo Hamamoto, Yoon-Koo Kang, Vladimir M Moiseyenko, Atsushi Ohtsu, Eric Van Cutsem, Nedal Al-Sakaffi, Alexa Urspruchi Julie Hill, Harald A Weber, and Hyun-Cheol Chung, for the ToGA Trial Investigators
The Oncologist 2014; 19:712-719; first published on June 20, 2014; doi:10.1634/theoncologist.2014-0058

基因表达分析对指导 II 期结肠癌治疗决策的最新进展
Current Status of Gene Expression Profiling to Assist Decision Making in Stage II Colon Cancer
Cheng E Chee and Neal J Meropol
The Oncologist 2014; 19:704-711; first published on May 28, 2014; doi:10.1634/theoncologist.2013-0471

评估 Oncotype DX 结肠癌测定结果对 II 期结肠癌患者的治疗建议有何影响的一项前瞻性多中心研究
Prospective Multi-Center Study Of The Impact Of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients
Geetika Srivastava, Lindsay A. Renfro, Robert J. Behrens, Margarita Lopatin, Calvin Choo, Gamini S. Soori, Shaker R. Dakhil, Rex B. Mowat, J. Philip Kuebler, George Kim, Miroslaw Mazurczak, Mark Lee, Steven R Alberts
The Oncologist 2014; 19:492-497; first published on April 7, 2014; doi:10.1634/theoncologist.2013-0401

采用一项随机对照试验（日本临床肿瘤组 9912）的数据确定日本晚期胃癌患者的预后因素
Determination of Prognostic Factors in Japanese Patients with Advanced Gastric Cancer Using the Data from a Randomized Controlled Trial, Japan Clinical Oncology Group 9912
Daisuke Takahari, Narikazu Boku, Junki Mizusawa, Atsuo Takashima, Yasuhide Yamada, Takayuki Yoshino, Kentaro Yamazaki, Wasaburo Koizumi, Kazutoshi Fukase, Kensei Yamaguchi, Masahiro Goto, Tomohiro Nishina, Takao Tamura, Akihito Tsuji, Atsushi Ohtsu
The Oncologist 2014; 19:358-366; first published on March 25, 2014; doi:10.1634/theoncologist.2013-0306

分子改变和靶向治疗对阑尾腺癌的影响
Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas
Kanwal P.S. Raghav, Aditya V. Shetty, Syed M.A. Kazmi, Nianxiang Zhang, Jeffrey Morris, Melissa Taggart, Keith Fournier, Richard Royal, Paul Mansfield, Cathy Eng, Robert A. Wolff, Michael J. Overman
The Oncologist 2013; 18:1270-1277; first published on October 22, 2013; doi:10.1634/theoncologist.2013-0186

酪氨酸激酶抑制剂疗法在胃肠间质瘤中的应用优化：探讨持续激酶抑制的益处
Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression
Axel Le Cesne, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu
The Oncologist 2013; 18:1192-1199; first published on October 17, 2013; doi:10.1634/theoncologist.2012-0361

胃癌辅助治疗：化疗与放疗
Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation
Noman Ashraf, Sarah Hoffe, Richard Kim
The Oncologist 2013; 18:1013-1021; first published on August 21, 2013; doi:10.1634/theoncologist.2012-0462

贝伐珠单抗用于转移性结直肠癌的有效性和安全性：来自7项随机对照研究的汇总分析
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
Herbert I. Hurwitz, Niall C. Tebbutt, Fairooz Kabbinavar, Bruce J. Giantonio, Zhong-Zhen Guan, Lada Mitchell, Daniel Waterkamp, Josep Tabernero
The Oncologist 2013; 18:1004-1012; first published on July 23, 2013; doi:10.1634/theoncologist.2013-0107

晚期食管癌的基因改变可能推动亚型特异性的治疗
Genomic Alterations in Advanced Esophageal Cancer May Lead to Subtype-Specific Therapies
Patrick M. Forde, Ronan J. Kelly
The Oncologist 2013; 18:823-832; first published on July 12, 2013; doi:10.1634/theoncologist.2013-0130

经选局部晚期直肠癌患者新辅助治疗策略
Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies
Alice Dewdney, David Cunningham, Ian Chau
The Oncologist 2013; 18:833-842; first published on July 2, 2013; doi:10.1634/theoncologist.2013-0022

伊马替尼辅助治疗胃肠道间质瘤的疗效与经济学价值
Efficacy and Economic Value of Adjuvant Imatinib for Gastrointestinal Stromal Tumors
Piotr Rutkowski, Alessandro Gronchi
The Oncologist 2013; 18:689-696; first published on May 24, 2013; doi:10.1634/theoncologist.2012-0474

贝伐珠单抗治疗相关早期高血压及临床结局分析：7项III期研究结果
Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies
Herbert I. Hurwitz, Pamela S. Douglas, John P. Middleton, George W. Sledge, David H. Johnson, David A. Reardon, Dafeng Chen, Oliver Rosen
The Oncologist 2013; 18:273-280; first published on March 13, 2013; doi:10.1634/theoncologist.2012-0339

术前西妥昔单抗、伊立替康、顺铂联合放疗在局部晚期食管癌患者中的治疗
Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer
Michael S. Lee, Harvey J. Mamon, Theodore S. Hong, Noah C. Choi, Panagiotis M. Fidias, Eunice L. Kwak, Jeffrey A. Meyerhardt, David P. Ryan, Raphael Bueno, Dean M. Donahue, Michael T. Jaklitsch, Michael Lanuti, David W. Rattner, Charles S. Fuchs, Peter C. Enzinger
The Oncologist 2013; 18:281-287; first published on February 21, 2013; doi:10.1634/theoncologist.2012-0208

依维莫司联合畅销缓释奥曲肽用于结直肠神经内分泌肿瘤患者：RADIANT-2 III期研究的亚组分析
Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study
Daniel Castellano, Emilio Bajetta, Ashok Panneerselvam, Stephen Saletan, Walter Kocha, Thomas O'Dorisio, Lowell B. Anthony, Timothy Hobday, for the RADIANT-2 Study Group
The Oncologist 2013; 18:46-53; first published on December 21, 2012; doi:10.1634/theoncologist.2012-0263

Top of Page

TERT 启动子突变和 TERT mRNA 而非 FGFR3 突变是中国汉族膀胱尿路上皮癌患者的尿生物标志物
TERT Promoter Mutations and TERT mRNA but Not FGFR3 Mutations Are Urinary Biomarkers in Han Chinese Patients With Urothelial Bladder Cancer
Kun Wang, Tiantian Liu, Cheng Liu, Yan Meng, Xiaotian Yuan, Li Liu, Nan Ge, Jikai Liu, Chang Wang, Hongbo Ren, Keqiang Yan, Sanyuan Hu, Zhonghua Xu, Yidong Fan, Dawei Xu
The Oncologist 2015; 20:263-269; first published on February 5, 2015; doi:10.1634/theoncologist.2014-0391

肾细胞癌的辅助疗法：过去、现在和将来
Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
Sumanta K. Pal, Naomi B. Haas
The Oncologist 2014; 19:851-859; first published on June 26, 2014; doi:10.1634/theoncologist.2014-0105

生殖细胞肿瘤的化疗后手术治疗 — 我们在过去 35 年内学到了什么？
Postchemotherapy Surgery for Germ Cell Tumors—What Have We Learned in 35 years?
Stephen B. Riggs, Earle F. Burgess, Kris E. Gaston, Caroline A. Merwarth, Derek Raghavan
The Oncologist 2014; 19:498-506; first published on April 9, 2014; doi:10.1634/theoncologist.2013-0379

主动吸烟可能对受舒尼替尼治疗的转移性肾细胞癌患者的反应率、无疾病进展生存期以及总生存期产生不良影响
Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, Natalie Maimon, Avivit Peer, Avivit Neumann, Hans Hammers, Mario A. Eisenberger, Victoria Sinibaldi, Roberto Pili, Henry Hayat, Svetlana Kovel, Avishay Sella, Ben Boursi, Rony Weitzen, Wilmosh Mermershtain, Keren Rouvinov, Raanan Berger, Michael A. Carducci
The Oncologist 2014; 19:51-60; first published on December 5, 2013; doi:10.1634/theoncologist.2012-0335

Top of Page

表皮生长因子受体（EGFR）酪氨酸激酶抑制剂治疗与挽救性化疗用于EGFR突变老年肺腺癌患者
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients
Yen-Han Tseng, Yen-Chiang Tseng, Yi-hsuan Lin, Yu-Chin Lee, Reury-Perng Perng, Jacqueline Whang-Peng, Yuh-Min Chen
The Oncologist 2015; 20:758-766; first published on June 8, 2015; doi:10.1634/theoncologist.2014-0352

老年患者局部食管癌的施治管理
Management of Localized Esophageal Cancer in the Older Patient
Elizabeth Won, David H. Ilson
The Oncologist 2014; 19:367-374; first published on March 24, 2014; doi:10.1634/theoncologist.2013-0178

化疗在老年与非老年III期结肠癌患者中的相对有效性和安全性：系统性回顾
Relative Effectiveness and Safety of Chemotherapy in Elderly and Nonelderly Patients With Stage III Colon Cancer: A Systematic Review
Anna Hung, C. Daniel Mullins
The Oncologist 2013; 18:54-63; first published on January 8, 2013; doi:10.1634/theoncologist.2012-0050

基于计算机的自填问卷的癌症特异性老年评估在胃肠道恶性肿瘤老年患者中的可行性
Feasibility of Computer-Based Self-Administered Cancer-Specific Geriatric Assessment in Older Patients With Gastrointestinal Malignancy
Nadine J. McCleary, Devin Wigler, Donna Berry, Kaori Sato, Thomas Abrams, Jennifer Chan, Peter Enzinger, Kimmie Ng, Brian Wolpin, Deborah Schrag, Charles S. Fuchs, Arti Hurria, Jeffrey A. Meyerhardt
The Oncologist 2013; 18:64-72; first published on January 3, 2013; doi:10.1634/theoncologist.2012-0241

Top of Page

曲妥珠单抗使用在资源有限和资源丰富地区的差异及其为HER2阳性乳腺癌患者带来的生存获益：一项中国的真实世界研究
Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China
Jianbin Li, Shusen Wang, Yongsheng Wang, Xiaojia Wang, Haibo Wang, Jifeng Feng, Qingyuan Zhang, Tao Sun, Quchang Ouyang, Yongmei Yin, Yinhua Liu, Cuizhi Geng, Min Yan, Zefei Jiang
The Oncologist 2017; 22:1333-1338; first published on August 10, 2017; doi:10.1634/theoncologist.2017-0088

中国实体瘤患者的临终化疗
Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies
Jin Sheng, Ya‐Xiong Zhang, Xiao‐Bo He, Wen‐Feng Fang, Yun‐Peng Yang, Gui‐Nan Lin, Xuan Wu, Ning Li, Jing Zhang, Lin‐Zhu Zhai, Yuan‐Yuan Zhao, Yan Huang, Ning‐Ning Zhou, Hong‐Yun Zhao, Li Zhang
The Oncologist 2017; 22:53-60; first published on October 27, 2016; doi:10.1634/theoncologist.2016-0013

对全身治疗反应不一显示出非小细胞肺癌患者可能存在遗传异质性且生存期不佳
Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non‐Small Cell Lung Cancer
Zhong‐Yi Dong, Hao‐Ran Zhai, Qing‐Yi Hou, Jian Su, Si‐Yang Liu, Hong‐Hong Yan, Yang‐Si Li, Zhi‐Yong Chen, Wen‐Zhao Zhong, Yi‐Long Wu
The Oncologist 2017; 22:61-69; doi:10.1634/theoncologist.2016-0150

华东地区癌症患者中癌症相关疲乏的流行情况与相关因素
Prevalence and Associated Factors of Cancer-Related Fatigue Among Cancer Patients in Eastern China
Li Tian, Lu Lin, Hui L. Li, Ke J. Chen, Xiao J. Zhang, Shu J. Qian, Yan Hu
The Oncologist 2016; 21:1349-1354; first published on July 22, 2016; doi:10.1634/theoncologist.2015-0537

评价careHPV、Cervista人乳头瘤病毒检测及第二代杂交捕获法在诊断新疆维吾尔族妇女宫颈上皮内瘤变2级及以上级别病变中的应用
Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women
Gulixian Tuerxun, Awaguli Yukesaier, Ling Lu, Kailibinuer Aierken, Patiman Mijiti, Yujie Jiang, Axianguli Abulizi, Yuanyuan Zhang, Guzhanuer Abuduxikuer, Guzhalinuer Abulizi, Hua Li
The Oncologist 2016; 21:825-831; first published on June 17, 2016; doi:10.1634/theoncologist.2015-0447

中国乳腺恶性肿瘤根治术治疗方法的演变趋势：为期10年的回顾性多中心研究
Trends of Radical Surgical Treatment Methods for Breast Malignancies in China: A Multicenter 10-Year Retrospective Review
Bai-Lin Zhang, Priya G. Sivasubramaniam, Qian Zhang, Jing Wang, Bin Zhang, Ji-Dong Gao, Zhong-Hua Tang, Guo-Ji Chen, Xiao-Ming Xie, Zhongzhao Wang, Hong-Jian Yang, Jian-Jun He, Hui Li, Jia-Yuan Li, Jin-Hu Fan, Xiang Wang, You-Lin Qiao
The Oncologist 2015; 20:1036-1043; first published on August 7, 2015; doi:10.1634/theoncologist.2014-0281

乳腺癌的差异：中国与美国肿瘤诊断、特征和手术治疗的多中心比较
Breast Cancer Disparities: A MultiCenter Comparison Between Tumor Diagnosis, Characteristics, and Surgical Treatment in China and the U.S.
Priya G. Sivasubramaniam, Bai-Lin Zhang, Qian Zhang, Jennifer S. Smith, Bin Zhang, Zhong-Hua Tang, Guo-Ji Chen, Xiao-Ming Xie, Xiao-Zhou Xu, Hong-Jian Yang, Jian-Jun He, Hui Li, Jia-Yuan Li, Jin-Hu Fan, You-Lin Qiao
The Oncologist 2015; 20:1044-1050; first published on August 3, 2015; doi:10.1634/theoncologist.2014-0290

中国乳腺癌的挑战与筛查：来自当前登记数据及人群筛查研究的经验
Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies
Qing-Kun Song, Xiao-Li Wang, Xin-Na Zhou, Hua-Bing Yang, Yu-Chen Li, Jiang-Ping Wu, Jun Ren, Herbert Kim Lyerly
The Oncologist 2015; 20:773-779; first published on May 22, 2015; doi:10.1634/theoncologist.2014-0351

2010年中国成年女性子宫颈癌筛查
Cervical Cancer Screening Among Adult Women in China, 2010
Baohua Wang, Minfu He, Ann Chao, Michael M. Engelgau, Mona Saraiya, Limin Wang, Linhong Wang
The Oncologist 2015; 20:627-634; first published on May 8, 2015; doi:10.1634/theoncologist.2014-0303

中国、印度和巴基斯坦年轻肿瘤科医生对癌症治疗的需求中存在的地区性差异
Regional Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan
H. Kim Lyerly, Maria R. Fawzy, Zeba Aziz, Reena Nair, C.S. Pramesh, Vani Parmar, Purvish M. Parikh, Rozmin Jamal, Azizunissa Irumnaz, Jun Ren, Martin R. Stockler, Amy P. Abernethy
The Oncologist 2015; 20:532-538; first published on April 17, 2015; doi:10.1634/theoncologist.2014-0213

低社会经济地位与工作年龄罹患终末期癌症患者更积极的临终治疗相关
Low Socioeconomic Status Is Associated With More Aggressive End-of-Life Care for Working-Age Terminal Cancer Patients
Chun-Ming Chang, Chin-Chia Wu, Wen-Yao Yin, Shiun-Yang Juang, Chia-Hui Yu, Ching-Chih Lee
The Oncologist 2014; 19:1241-1248; first published on October 23, 2014; doi:10.1634/theoncologist.2014-0152

中国肺癌治疗差异：待解之题
Lung Cancer Treatment Disparities in China: A Question Needed to Answer
Yi-Long Wu, Lulu Yang, Xuchao Zhang, XueNing Yang, JinJi Yang, Zhen Wang, HuaJun Chen, Honghong Yan, Chongrui Xu, Jilin Guan, Yanyan He, WenZhao Zhong, SheJuan An
The Oncologist 2014, 19:1084-1090. doi: 10.1634/theoncologist.2014-0007 originally published online September 15, 2014

全球临床癌症研究的障碍与挑战
Barriers and Challenges to Global Clinical Cancer Research
Bostjan Seruga, Aleksander Sadikov, Eduardo L. Cazap, Lucia Beatriz Delgado, Raghunadharao Digumarti, Natasha B. Leighl, Mohamed M. Meshref, Hironobu Minami, Eliezer Robinson, Nise Hitomi Yamaguchi, Doug Pyle, Tanja Cufer
The Oncologist 2014; 19:61-67; first published on December 9, 2013; doi:10.1634/theoncologist.2013-0290

以醋酸染色肉眼观察法和冷冻疗法作为筛查和治疗方法预防宫颈癌：来自秘鲁、乌干达和越南示范性项目的经验、观念和信心
Screen-and-Treat Approach to Cervical Cancer Prevention Using Visual Inspection With Acetic Acid and Cryotherapy: Experiences, Perceptions, and Beliefs From Demonstration Projects in Peru, Uganda, and Vietnam
Proma Paul, Jennifer L. Winkler, Rosario M. Bartolini, Mary E. Penny, Trinh Thu Huong, Le Thi Nga, Edward Kumakech, Emmanuel Mugisha, Jose Jeronimo
The Oncologist 2013; 18:1278-1284; first published on November 11, 2013; doi:10.1634/theoncologist.2013-0253

Top of Page

2型糖尿病对亚洲早期子宫颈癌患者预后的影响
The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia
Hung-Yang Kuo, Zhong-Zhe Lin, Raymond Kuo, Wen-Yi Shau, Chiu-Lin Lai, Yen-Yun Yang, Yu-Yun Shao, Chiun Hsu, Wen-Fan Cheng, Ann-Lii Cheng, James Chih-Hsin Yang, Mei-Shu Lai
The Oncologist 2015; 20:1051-1057; first published on August 3, 2015; doi:10.1634/theoncologist.2015-0111

以铂类为基础的辅助治疗方案对卵巢交界性肿瘤伴浸润性种植患者转归的影响：meta分析
A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants
Ines Vasconcelos, Jessica Olschewski, Ioana Braicu, Jalid Sehouli
The Oncologist 2015; 20:151-158; first published on January 19, 2015; doi:10.1634/theoncologist.2014-0144

多囊卵巢综合征女性发生子宫、卵巢和乳腺癌的风险：基于全台人群的回顾性队列研究
A Nationwide Population-Based Retrospective Cohort Study of the Risk of Uterine, Ovarian, and Breast Cancer in Women with Polycystic Ovary Syndrome
Cheng-Che Shen, Albert C. Yang, Jeng-Hsiu Hung, Li-Yu Hu, Shih-Jen Tsai
The Oncologist 2015; 20:45-49; first published on November 19, 2014; doi:10.1634/theoncologist.2014-0311

贝伐单抗在高危卵巢癌中的应用 — 一项成本效益分析
Bevacizumab in Treatment of High-Risk Ovarian Cancer—A Cost-Effectiveness Analysis
John K Chan, Thomas J. Herzog, Lilian Hu, Bradley J. Monk, Tuyen Kiet, Kevin Blansit, Daniel S. Kapp, Xinhua Yu
The Oncologist 2014; 19:523-527; first published on April 10, 2014; doi:10.1634/theoncologist.2013-0322

PTEN/PI3K/Akt 通路对上皮性卵巢癌的预后作用： 一项荟萃分析
The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis
Jing Cai, Linjuan Xu, Huijuan Tang, Qiang Yang, Xiaoqing Yil, Yan Fang, Ying Zhu, Zehua Wang
The Oncologist 2014; 19:528-535; first published on April 9, 2014; doi:10.1634/theoncologist.2013-0333

中国宫颈癌患病率及临床特征变化分析：一项全国性样本中10 012名病例的研究
Changes in Prevalence and Clinical Characteristics of Cervical Cancer in the People's Republic of China: A Study of 10,012 Cases From a Nationwide Working Group
Shuang Li, Ting Hu, Weiguo Lv, Hang Zhou, Xiong Li, Ru Yang, Yao Jia, Kecheng Huang, Zhilan Chen, Shaoshuai Wang, FangXu Tang, Qinghua Zhang, Jian Shen, Jin Zhou, Ling Xi, Dongrui Deng, Hui Wang, Shixuan Wang, Xing Xie, Ding Ma
The Oncologist 2013; 18:1101-1107; first published on September 16, 2013; doi:10.1634/theoncologist.2013-0123

在存在病损风险的局部晚期宫颈癌患者中比较以卡铂为基础和以顺铂基础的同步放化疗方案
Comparison of Carboplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients With Morbidity Risks
Eun Ji Nam, Maria Lee, Ga Won Yim, Jae Hoon Kim, Sunghoon Kim, Sang Wun Kim, Jae Wook Kim, Young Tae Kim
The Oncologist 2013; 18:843-849; first published on July 2, 2013; doi:10.1634/theoncologist.2012-0455

姑息性手术在妇科癌症患者中的作用
The Role of Palliative Surgery in Gynecologic Cancer Cases
Joanie Mayer Hope, Bhavana Pothuri
The Oncologist 2013; 18:73-79; first published on January 8, 2013; doi:10.1634/theoncologist.2012-0328

Top of Page

针刺治疗用于头颈癌患者的化放疗相关性吞咽困难：初步假对照临床试验
Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial
Weidong Lu, Peter M. Wayne, Roger B. Davis, Julie E. Buring, Hailun Li, Eric A. Macklin, Jochen H. Lorch, Elaine Burke, Tyler C. Haddad, Laura A. Goguen, David S. Rosenthal, Roy B. Tishler, Marshall R. Posner, Robert I. Haddad
The Oncologist 2016; 21:1522-1529; first published on August 10, 2016; doi:10.1634/theoncologist.2015-0538

局部晚期鼻咽癌患者同步放化疗中顺铂累积剂量的预后价值：前瞻性III期临床试验的次要分析
Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial
Hao Peng, Lei Chen, Yuan Zhang, Wen-Fei Li, Yan-Ping Mao, Fan Zhang, Rui Guo, Li-Zhi Liu, Ai-Hua Lin, Ying Sun, Jun Ma
The Oncologist 2016; 21:1369-1376; first published on August 5, 2016; doi:10.1634/theoncologist.2016-0105

对于鼻咽癌患者而言，[18F]-氟脱氧葡萄糖正电子发射断层扫描标准摄取值可作为辅助化疗获益的预测指标
[18F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Value as a Predictor of Adjuvant Chemotherapy Benefits in Patients With Nasopharyngeal Carcinoma
Te-Chun Hsieh, Ching Yun Hsieh, Tse Yen Yang, Tzu Ting Chen, Chen Yuan Lin, Ching-Chan Lin, Chung Hung Hua, Chang-Fang Chiu, Su-Peng Yeh, Yuh Pyng Sher
The Oncologist 2015; 20:539-545; first published on April 15, 2015; doi:10.1634/theoncologist.2014-0291

仅具有骨转移的鼻咽癌患者的 M1 期细分和治疗转归
M1 Stage Subdivision and Treatment Outcome of Patients With Bone-Only Metastasis of Nasopharyngeal Carcinoma
Lujun Shen, Jun Dong, Sheng Li, Yue Wang, Annan Dong, Wanhong Shu, Ming Wu, Changchuan Pan, Yunfei Xia, Peihong Wu
The Oncologist 2015; 20:291-298; first published on February 6, 2015; doi:10.1634/theoncologist.2014-0206

抗表皮生长因子受体治疗用于头颈部鳞状细胞癌：聚焦耐药的潜在分子机制
Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
Carolien Boeckx, Marc Baay, An Wouters, Pol Specenier, Jan B. Vermorken, Marc Peeters, Filip Lardon
The Oncologist 2013; 18:850-864; first published on July 2, 2013; doi:10.1634/theoncologist.2013-0013

螺旋断层放射治疗在头颈部癌中的潜在价值
The Potential of Helical Tomotherapy in the Treatment of Head and Neck Cancer
Dirk Van Gestel, Dirk Verellen, Lien Van De Voorde, Bie de Ost, Geert De Kerf, Olivier Vanderveken, Carl Van Laer, Danielle Van den Weyngaert, Jan B. Vermorken, Vincent Gregoire
The Oncologist 2013; 18:697-706; first published on May 30, 2013; doi:10.1634/theoncologist.2012-0424

Top of Page

癌症死亡患者在生命最后一年内的健康护理费用日渐增加：来自台湾一项回顾性人群队列研究的十年证据
Escalating Health Care Expenditures in Cancer Decedents' Last Year of Life: A Decade of Evidence from a Retrospective Population‐Based Cohort Study in Taiwan
Yen‐Ni Hung, Tsang‐Wu Liu, Fur‐Hsing Wen, Wen‐Chi Chou, Siew Tzuh Tang
The Oncologist 2017; 22:460-469; first published on February 23, 2017; doi:10.1634/theoncologist.2016-0283

Top of Page

肝胆多学科专家组评估对结直肠癌肝转移患者的影响：一项基于人群的研究
The Impact of a Hepatobiliary Multidisciplinary Team Assessment in Patients with Colorectal Cancer Liver Metastases: A Population‐Based Study
Jennie Engstrand, Nikolaos Kartalis, Cecilia Strömberg, Mats Broberg, Anna Stillström, Tobias Lekberg, Eduard Jonas, Jacob Freedman, Henrik Nilsson
The Oncologist 2017; 22:1067-1074; first published on May 26, 2017; doi:10.1634/theoncologist.2017-0028

使用预后列线图对无门静脉癌栓的肝细胞癌患者行根治切除术后的生存期进行分层
Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection
Yi‐Peng Fu, Yong Yi, Jin‐Long Huang, Chu‐Yu Jing, Jian Sun, Xiao‐Chun Ni, Zhu‐Feng Lu, Ya Cao, Jian Zhou, Jia Fan, Shuang‐Jian Qiu
The Oncologist 2017; 22:561-569; first published on April 24, 2017; doi:10.1634/theoncologist.2016-0231

起始不可手术肝细胞癌患者在行经动脉化疗栓塞治疗降期后是否有必要进行挽救性肝切除？10年经验
Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience
Yingqiang Zhang, Guihua Huang, Yu Wang, Lijian Liang, Baogang Peng, Wenzhe Fan, Jianyong Yang, Yonghui Huang, Wang Yao, Jiaping Li
The Oncologist 2016; 21:1442-1449; first published on August 2, 2016; doi:10.1634/theoncologist.2016-0094

索拉非尼在晚期肝细胞癌中的有效性
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
Hanna K. Sanoff, YunKyung Chang, Jennifer L. Lund, Bert H. O’Neil, Stacie B. Dusetzina
The Oncologist 2016; 21:1113-1120; first published on May 16, 2016; doi:10.1634/theoncologist.2015-0478

结直肠癌肝转移肝切除术后的早期复发：最佳定义是什么？预测因素又是什么？
Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors?
Katsunori Imai, Marc-Antoine Allard, Carlos Castro Benitez, Eric Vibert, Antonio Sa Cunha, Daniel Cherqui, Denis Castaing, Henri Bismuth, Hideo Baba, René Adam
The Oncologist 2016; 21:887-894; first published on April 28, 2016; doi:10.1634/theoncologist.2015-0468

美国40年间胆管癌的发病率变化趋势：肝内病变的发病率正在升高
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Supriya K. Saha, Andrew X. Zhu, Charles S. Fuchs, Gabriel A. Brooks
The Oncologist 2016; 21:594-599; first published on March 21, 2016; doi:10.1634/theoncologist.2015-0446

纤维板层型肝细胞癌相关性高氨血症性脑病：案例报告、文献综述与建议治疗方案
Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm
Claudia I. Chapuy, Inderneel Sahai, Rohit Sharma, Andrew X. Zhu, Olga N. Kozyreva
The Oncologist 2016; 21:514-520; first published on March 14, 2016; doi:10.1634/theoncologist.2015-0267

索拉非尼联合或不联合动脉化疗栓塞治疗晚期肝细胞癌合并门静脉主干癌栓：回顾性分析
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis
Yingqiang Zhang, Wenzhe Fan, Yu Wang, Ligong Lu, Sirui Fu, Jianyong Yang, Yonghui Huang, Wang Yao, Jiaping Li
The Oncologist 2015; 20:1417-1424; first published on October 7, 2015; doi:10.1634/theoncologist.2015-0196

使用18F-氟脱氧葡萄糖正电子发射断层扫描的晚期胆道癌的代谢特征及其临床意义
Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-FDG PET and Their Clinical Implications
Do-Youn Oh, Kyoung Min Cho, Tae-Yong Kim, Kyung Hun Lee, Sae-Won Han, Seock-Ah Im, Tae You Kim, Yung-Jue Bang
The Oncologist 2015; 20:926-933; first published on June 22, 2015; doi: 10.1634/theoncologist.2014-0356

肝内胆管癌肝切除术后根据生存风险分层进行辅助动脉化疗栓塞
Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification
Jun Li, Qing Wang, Zhengqing Lei, Dong Wu, Anfeng Si, Kui Wang, Xuying Wan, Yizhou Wang, Zhenlin Yan, Yong Xia, Wan Yee Lau, Mengchao Wu, Feng Shen
The Oncologist 2015; 20:640-647; first published on May 8, 2015; doi:10.1634/theoncologist.2014-0470

FOLFOX4方案与多柔比星在中国进展期肝细胞癌患者中的有效性和安全性：EACH研究的亚组分析结果
The Efficacy and Safety of the Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX4) Regimen Compared With Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Phase III, Multicenter, Randomized, Open Label Trial (EACH Study Chinese Subgroup Analysis)
Shukui Qin, Ying Cheng, Jun Liang, Lin Shen, Yuxian Bai, Jianfeng Li, Jia Fan, Lijian Liang,Yaqi Zhang, Gang Wu, Kun-Ming Rau, Tsai-Shen Yang, Zhixiang Jian , Houjie Liang, Yan Sun
The Oncologist 2014, 19:1169-1178. doi: 10.1634/theoncologist.2014-0190 originally published online September 15, 2014

肝脏肿瘤的放射疗法：已准备好纳入指南？
Radiation Therapy for Liver Rumors: Ready for Inclusion in Guidelines?
Shyam K. Tanguturi, Jennifer Y. Wo, Andrew X. Zhu, Laura A. Dawson, Theodore S. Hong
The Oncologist 2014; 19:868-879; first published on July 7, 2014; doi:10.1634/theoncologist.2014-0097

接受索拉非尼治疗的晚期肝细胞癌患者中，替代疗效标准（Choi、欧洲肝脏研究学会和改良的实体瘤疗效评价标准 [RECIST]）与 RECIST 1.1 的比较
Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST] Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated with Sorafenib
Maxime Ronot, Mohamed Bouattour, Johanna Wassermann, Onorina Bruno, Chantal Dreyer, Béatrice Larroque, Laurent Castera, Valérie Vilgrain, Jacques Belghiti, Eric Raymond, Sandrine Faivre
The Oncologist 2014; 19:394-402; first published on March 20, 2014; doi:10.1634/theoncologist.2013-0114

HIV感染患者肝细胞癌的肝移植：意大利多中心经验
Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients
Fabrizio Di Benedetto, Giuseppe Tarantino, Giorgio Ercolani, Umberto Baccarani, Roberto Montalti, Nicola De Ruvo, Massimiliano Berretta, Gian Luigi Adani, Matteo Zanello, Marcello Tavio, Nicola Cautero, Umberto Tirelli, Antonio D. Pinna, Giorgio E Gerunda, Giovanni Guaraldi
The Oncologist 2013; 18:592-599; first published on May 10, 2013; doi:10.1634/theoncologist.2012-0255

晚期肝细胞肝癌的抗血管生成治疗
Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma
Keeran R. Sampat, Bert O'Neil
The Oncologist 2013; 18:430-438; first published on April 10, 2013; doi:10.1634/theoncologist.2012-0388

Top of Page

手术可切除、局限期和广泛期的小细胞肺癌的治疗现状
Current Treatments for Surgically Resectable, Limited‐Stage, and Extensive‐Stage Small Cell Lung Cancer
Thomas E. Stinchcombe
The Oncologist 2017; 22:1510-1517; first published on August 4, 2017; doi:10.1634/theoncologist.2017-0204

吉非替尼一线治疗表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌患者的总生存期预后因素的真实世界数据
Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib
Zong‐Han Yao, Wei‐Yu Liao, Chao‐Chi Ho, Kuan‐Yu Chen, Jin‐Yuan Shih, Jin‐Shing Chen, Zhong‐Zhe Lin, Chia‐Chi Lin, James Chih‐Hsin Yang, Chong‐Jen Yu
The Oncologist 2017; 22:1075-1083; first published on May 15, 2017; doi:10.1634/theoncologist.2016-0331

BRAF突变型非小细胞肺癌的靶向治疗：从分子表达谱到合理设计治疗
Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
Christina S. Baik, Nathaniel J. Myall, Heather A. Wakelee
The Oncologist 2017; 22:786-796; first published on May 9, 2017; doi:10.1634/theoncologist.2016-0458

中性粒细胞-淋巴细胞比值可作为接受过综合治疗的局部晚期（IIIA和IIIB期）非小细胞肺癌患者的预后标志物
Neutrophil‐Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non‐Small Cell Lung Cancer Treated with Combined Modality Therapy
Katherine A. Scilla, Søren M. Bentzen, Vincent K. Lam, Pranshu Mohindra, Elizabeth M. Nichols, Melissa A. Vyfhuis, Neha Bhooshan, Steven J. Feigenberg, Martin J. Edelman, Josephine L. Feliciano
The Oncologist 2017; 22:737-742; first published on May 22, 2017; doi:10.1634/theoncologist.2016-0443

以无进展生存期替代总生存期作为恶性间皮瘤研究终点的方法验证：癌症和白血病工作组B与中北部癌症治疗组（联合）试验分析
Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Xiaofei Wang, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke, Alex A. Adjei, Hedy L. Kindler, Everett E. Vokes, Herbert Pang
The Oncologist 2017; 22:189-198; first published on February 10, 2017; doi:10.1634/theoncologist.2016-0121

非小细胞肺癌中的KRAS通路靶点
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Pascale Tomasini, Preet Walia, Catherine Labbe, Kevin Jao, Natasha B. Leighl
The Oncologist 2016; 21:1450-1460; first published on November 2, 2016; doi:10.1634/theoncologist.2015-0084

液体诊断平台在非小细胞肺癌中的临床应用
Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer
Benjamin Levy, Zishuo I. Hu, Kristen N. Cordova, Sandra Close, Karen Lee, Daniel Becker
The Oncologist 2016; 21:1121-1130; first published on July 7, 2016; doi:10.1634/theoncologist.2016-0082

免疫治疗在小细胞肺癌治疗中的前景
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Leora Horn, Martin Reck, David R. Spigel
The Oncologist 2016; 21:910-921; first published on June 27, 2016; doi:10.1634/theoncologist.2015-0523

在疾病进展的新时代中重新评估疾病进展：间变性淋巴瘤激酶阳性非小细胞肺癌的一线和二线治疗综述
Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Emily H. Castellanos, Leora Horn
The Oncologist 2016; 21:755-761; first published on April 6, 2016; doi:10.1634/theoncologist.2015-0396

综合性基因组分析可鉴别出荧光原位杂交检验未测出的对克唑替尼治疗有应答的ALK重排非小细胞肺癌患者亚组
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Siraj M. Ali, Thomas Hensing, Alexa B. Schrock, Justin Allen, Eric Sanford, Kyle Gowen, Atul Kulkarni, Jie He, James H. Suh, Doron Lipson, Julia A. Elvin, Roman Yelensky, Zachary Chalmers, Juliann Chmielecki, Nir Peled, Samuel J. Klempner, Kashif Firozvi, Garrett M. Frampton, Julian R. Molina, Smitha Menon, Julie R. Brahmer, Heber MacMahon, Jan Nowak, Sai-Hong Ignatius Ou, Marjorie Zauderer, Marc Ladanyi, Maureen Zakowski, Neil Fischbach, Jeffrey S. Ross, Phil J. Stephens, Vincent A. Miller, Heather Wakelee, Shridar Ganesan, Ravi Salgia
The Oncologist 2016; 21:762-770; first published on May 31, 2016; doi:10.1634/theoncologist.2015-0497

非小细胞肺癌中的MET外显子14跳读
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Rebecca S. Heist, Hyo Sup Shim, Shalini Gingipally, Mari Mino-Kenudson, Long Le, Justin F. Gainor, Zongli Zheng, Martin Aryee, Junfeng Xia, Peilin Jia, Hailing Jin, Zhongming Zhao, William Pao, Jeffrey A. Engelman, A. John Iafrate
The Oncologist 2016; 21:481-486; first published on March 28, 2016; doi:10.1634/theoncologist.2015-0510

表皮生长因子受体抑制剂在肺鳞癌治疗中的作用
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
Glenwood D. Goss, Johanna N. Spaans
The Oncologist 2016; 21:205-213; first published on January 14, 2016; doi:10.1634/theoncologist.2015-0209

厄洛替尼应答的晚期非小细胞肺癌患者发生进展后继续厄洛替尼治疗的II期随机研究
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
Balazs Halmos, Nathan A. Pennell, Pingfu Fu, Shumaila Saad, Shirish Gadgeel, Gregory A. Otterson, Tarek Mekhail, Michael Snell, J. Philip Kuebler, Neelesh Sharma, Afshin Dowlati
The Oncologist 2015; 20:1298-1303; first published on August 25, 2015; doi:10.1634/theoncologist.2015-0136

改变用途疗法对非小细胞肺癌的治疗作用：老树发新芽
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer (NSCLC): What's Old is New Again
Ashish Saxena, Daniel Becker, Isabel Preeshagul, Karen Lee, Elena Katz, Benjamin Levy
The Oncologist 2015; 20:934-94; first published on July 8, 2015; doi: 10.1634/theoncologist.2015-0064

吸烟状态对接受一线表皮生长因子受体(EGFR) 酪氨酸激酶抑制剂对比铂类双药化疗的携带 EGFR 突变活性的非小细胞肺癌患者无进展生存期的影响：前瞻性随机试验的meta分析
The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials
Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, Satomi Yamamoto, Shun-ichi Isa, Hideo Saka, Akihito Kubo, Tomoya Kawaguchi, Minoru Takada, Rafael Rosell, Takayasu Kurata, Sai-Hong Ignatius Ou
The Oncologist 2015; 20:307-315; first published on February 5, 2015; doi:10.1634/theoncologist.2014-0285

晚期野生型非小细胞肺癌一线治疗和维持治疗的复杂决定
Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer
Ryan D. Gentzler, Melissa L. Johnson
The Oncologist 2015; 20:299-306; first published on February 6, 2015; doi:10.1634/theoncologist.2014-0212

当前恶性胸膜间皮瘤面临的评估与管理问题
Current Issues in Malignant Pleural Mesothelioma Evaluation and Management
Jing Ai, James P. Stevenson
The Oncologist 2014; 19: 975-984

深入探讨：非小细胞肺癌的免疫治疗新策略
What Lies Within: Novel Strategies in Immunotherapy for Non-Small Cell Lung Cancer
Patrick M. Forde, Kim A. Reiss, Amer M. Zeidan, Julie R. Brahmer
The Oncologist 2013; 18:1203-1213; first published on October 8, 2013; doi:10.1634/theoncologist.2013-0171

厄洛替尼联合化疗或单纯化疗对产生 EGFR 酪氨酸激酶抑制剂获得性耐药的晚期非小细胞肺癌的疗效比较
Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Sarah B. Goldberg, Geoffrey R. Oxnard, Subba Digumarthy, Alona Muzikansky, David M. Jackman, Inga T. Lennes, Lecia V. Sequist
The Oncologist 2013; 18:1214-1220; first published on September 26, 2013; doi:10.1634/theoncologist.2013-0168

晚期非小细胞肺癌的二线治疗
Second-Line Therapy for Advanced NSCLC
Jared M. Weiss, Thomas E. Stinchcombe
The Oncologist 2013; 18:947-953; first published on August 5, 2013; doi:10.1634/theoncologist.2013-0096

非小细胞肺癌新靶点：ROS1与RET融合致癌基因
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Justin F. Gainor, Alice T. Shaw
The Oncologist 2013; 18:865-875; first published on June 28, 2013; doi:10.1634/theoncologist.2013-0095

肺鳞状细胞癌的基因组学
Genomics of Squamous Cell Lung Cancer
Melissa Rooney, Siddhartha Devarakonda, Ramaswamy Govindan
The Oncologist 2013; 18:707-716; first published on May 31, 2013; doi:10.1634/theoncologist.2013-0063

获准用于晚期非小细胞肺癌的系统性药物在临床实践中的疗效：一项SEER-Medicare分析
Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis
Taofeek K. Owonikoko, Camille Ragin, Zhengjia Chen, Sungjin Kim, Madhusmita Behera, Johann C. Brandes, Nabil Saba, Rebecca Pentz, Suresh S. Ramalingam, Fadlo R. Khuri
The Oncologist 2013; 18:600-610; first published on May 1, 2013; doi:10.1634/theoncologist.2012-0480

氨柔比星作为三线或四线化疗药物治疗非小细胞肺癌的II期研究：北海道肺癌临床研究组试验（HOT）0901
A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901
Toshiyuki Harada, Satoshi Oizumi, Kenichiro Ito, Kei Takamura, Eiki Kikuchi, Tomoya Kuda, Shunichi Sugawara, Aya Suzuki, Makoto Maemondo, Yuka Fujita, Ichiro Kinoshita, Akira Inoue, Fumihiro Hommura, Yutaka Katsuura, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura, Hokkaido Lung Cancer Clinical Study Group
The Oncologist 2013; 18:439-445; first published on February 26, 2013; doi:10.1634/theoncologist.2012-0308

非小细胞肺癌中MET受体酪氨酸激酶的作用及抗MET靶向药物的临床开发
The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents
Kyle W. Robinson, Alan B. Sandler
The Oncologist 2013; 18:115-122; first published on January 23, 2013; doi:10.1634/theoncologist.2012-0262

Top of Page

STAT3 抑制剂：在淋巴瘤和白血病中找到归宿
Stat3 Inhibitors: Finding a Home in Lymphoma and Leukemia
Javier Munoz, Navjot Dhillon, Filip Janku, Stephanie S. Watowich, David S. Hong
The Oncologist 2014; 19:536-544; first published on April 4, 2014; doi:10.1634/theoncologist.2013-0407

罕见病理类型的原发性眼附属器淋巴瘤的诊断和治疗再评价
A Reappraisal of Diagnostic and Therapeutic Management of Uncommon Forms of Primary Ocular Adnexal Lymphoma
Maurilio Ponzoni, Silvia Govi,, Giada Licata,, Silvia Mappa,, Antonio Giordano Resti, Letterio S. Politi, Lorenzo Spagnuolo, Eliana Di Cairano, Claudio Doglioni, Andrés J. M. Ferreri
The Oncologist 2013; 18:876-884; first published on June 28, 2013; doi:10.1634/theoncologist.2012-0425

白细胞介素-10基因多态性与霍奇金淋巴瘤患者避免治疗失败相关
Interleukin-10 Gene Polymorphisms are Associated With Freedom From Treatment Failure for Patients With Hodgkin Lymphoma
Nils Schoof, Jeremy Franklin, Robert Fürst, Thomas Zander, Frederike von Bonin, Frederic Peyrade, Lorenz Trümper, Volker Diehl, Andreas Engert, Dieter Kube, Daniel Re
The Oncologist 2013; 18:80-89; first published on January 8, 2013; doi:10.1634/theoncologist.2012-0291

Top of Page

照护我们中的一员
Caring for One of Our Own
Lidia Schapira, Lawrence S. Blaszkowsky, Barbara J. Cashavelly, Christina Y. Kim, John P. Riley, Mali C. Wold, David Ryan, Richard T. Penson
The Oncologist 2014; 19:545-549; first published on April 10, 2014; doi:10.1634/theoncologist.2014-0079

"我认为变异很大……"：一项关于肿瘤科医生对晚期癌症治疗决策的医学标准与其他因素的经验与观点的定性研究
"Well, I Think There Is Great Variation…": A Qualitative Study of Oncologists' Experiences and Views Regarding Medical Criteria and Other Factors Relevant to Treatment Decisions in Advanced Cancer
Jan Schildmann, Jacinta Tan, Sabine Salloch, Jochen Vollmann
The Oncologist 2013; 18:90-96; first published on January 3, 2013; doi:10.1634/theoncologist.2012-0206

Top of Page

循环肿瘤细胞、DNA和mRNA：在黑色素瘤患者中潜在的临床应用
Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma
Melody J. Xu, Jay F. Dorsey, Ravi Amaravadi, Giorgos Karakousis, Charles B. Simone II, Xiaowei Xu, Wei Xu, Erica L. Carpenter, Lynn Schuchter, Gary D. Kao
The Oncologist 2016; 21:84-94; first published on November 27, 2015; doi:10.1634/theoncologist.2015-0207

Ipilimumab及其毒性反应：多学科方法
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Leslie A. Fecher, Sanjiv S. Agarwala, F. Stephen Hodi, Jeffrey S. Weber
The Oncologist 2013; 18:733-743; first published on June 17, 2013; doi:10.1634/theoncologist.2012-0483

Ipilimumab用于晚期粘膜黑色素患者
Ipilimumab for Patients With Advanced Mucosal Melanoma
Michael A. Postow, Jason J. Luke, Mark J. Bluth, Nikhil Ramaiya, Katherine S. Panageas, Donald P. Lawrence, Nageatte Ibrahim, Keith T. Flaherty, Ryan J. Sullivan, Patrick A. Ott, Margaret K. Callahan, James J. Harding, Sandra P. D'Angelo, Mark A. Dickson, Gary K. Schwartz, Paul B. Chapman, Sacha Gnjatic, Jedd D. Wolchok, F. Stephen Hodi, Richard D. Carvajal
The Oncologist 2013; 18:726-732; first published on May 28, 2013; doi:10.1634/theoncologist.2012-0464

Ipilimumab、Vemurafenib、Dabrafenib以及Trametinib为BRAF突变恶性黑色素瘤临床管理中的协同竞争者
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Jason J. Luke, F. Stephen Hodi
The Oncologist 2013; 18:717-725; first published on May 24, 2013; Doi:10.1634/theoncologist.2012-0391

Top of Page

换位移情：一名肿瘤科医生的就医经历
Nurturing Empathy: An Oncologist Looks at Medicine and Himself
Fazlur Rahman
The Oncologist 2014; 19:1287-1288; first published on November 6, 2014; doi:10.1634/theoncologist.2014-0387

Top of Page

NOMS框架：脊柱转移瘤的治疗方法
The NOMS Framework: Approach to the Treatment of Spinal Metastatic Tumors
Ilya Laufer, David G. Rubin, Eric Lis, Brett W. Cox, Michael D. Stubblefield, Yoshiya Yamada, Mark H. Bilsky
The Oncologist 2013; 18:744-751; first published on May 24, 2013; doi:10.1634/theoncologist.2012-0293

Top of Page

医院开支强度与癌症转归之间的关联：在亚洲国家基于人群的研究
The Association of Hospital Spending Intensity and Cancer Outcomes: A Population-Based Study in an Asian Country
Ting-Shou Chang, Kuang-Yung Huang, Chun-Ming Chang, Chun-Hsuan Lin, Yu-Chieh Su, Ching-Chih Lee
The Oncologist 2014; 19: 990-998.

转移性结直肠癌老年患者中贝伐单抗一线疗法使用相关的生存期和寿命成本
Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients with Metastatic Colorectal Cancer
Veena Shankaran, David Mummy, Lisel Koepl , Aasthaa Bansal, Dana K. Mirick, Elaine Yu, Rob Morlock, Sarika Ogale, Scott D. Ramsey
The Oncologist 2014; 19:892-899; first published on August 1, 2014; doi:10.1634/theoncologist.2013-0209

生物标志物验证：常见的数据分析关注点
Biomarker Validation: Common Data Analysis Concerns
Joe E. Ensor
The Oncologist 2014; 19:886-891; first published on July 7, 2014; doi:10.1634/theoncologist.2014-0061

肿瘤学中的比较效益研究
Comparative Effectiveness Research in Oncology
Gary H. Lyman
The Oncologist 2013; 18:752-759; first published on May 22, 2013; doi:10.1634/theoncologist.2012-0445

肿瘤学比较效益研究：执行和报告原则的多方利益相关者观点
Oncology Comparative Effectiveness Research: A Multistakeholder Perspective on Principles for Conduct and Reporting
Scott D. Ramsey, Sean D. Sullivan, Shelby D. Reed, Ya-Chen Tina Shih, Ken Schaecher, Rahul Dhanda, Debra Patt, Kelly Pendergrass, Mark Walker, Jennifer Malin, Lee Schwartzberg, Kurt Neumann, Elaine Yu, Arliene Ravelo, Art Small
The Oncologist 2013; 18:760-767; first published on May 6, 2013; doi:10.1634/theoncologist.2012-0386

Top of Page

肿瘤患儿流行性感冒的防治
Protecting Pediatric Oncology Patients From Influenza
Leslie S. Kersun, Anne F. Reilly, Susan E. Coffin, Kathleen E. Sullivan
The Oncologist 2013; 18:204-211; first published on January 31, 2013; doi:10.1634/theoncologist.2012-0401

Top of Page

识别具有临床意义的结直肠癌分子亚型：新时代的曙光
Identification of Clinically Relevant Molecular Subtypes in Colorectal Cancer: The Dawning of a New Era
Patrick G. Johnston
The Oncologist 2014; 19:568-573; first published on April 9, 2014; doi:10.1634/theoncologist.2014-038

Top of Page

立体定向放射治疗联合酪氨酸激酶抑制剂用于治疗癌基因驱动的IV期肺癌
Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Meghan Campo, Hani Al-Halabi, Melin Khandekar, Alice T. Shaw, Lecia V. Sequist, Henning Willers
The Oncologist 2016; 21:964-973; first published on June 27, 2016; doi:10.1634/theoncologist.2015-0508

癌症治疗中的营养限入和放疗：少即是多
Nutrient Restriction and Radiation Therapy for Cancer Treatment: When Less Is More
Colin E. Champ, Renato Baserga, Mark V. Mishra, Lianjin Jin, Federica Sotgia, Michael P. Lisanti, Richard G. Pestell, Adam P. Dicker, Nicole L. Simone
The Oncologist 2013; 18:97-103; first published on January 8, 2013; doi:10.1634/theoncologist.2012-0164

Top of Page

欧洲药品管理局对博舒替尼用于治疗慢性髓性白血病成人患者的审查： 人用医药产品委员会的科学评估概要
The European Medicines Agency Review of Bosutinib for the Treatment of Adult Patients with Chronic Myelogenous Leukaemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Zahra Hanaizi, Christoph Unkrig, Harald Enzmann, Jorge Camarero, Arantxa Sancho-Lopez, Tomas Salmonson, Christian Gisselbrecht, Edward Laane, Francesco Pignatti
The Oncologist 2014; 19:421-425; first published on March 25, 2014; doi:10.1634/theoncologist.2013-0294

欧洲药品管理局评审匹杉琼用于治疗成人多复发性/难治性侵袭性非霍奇金B细胞淋巴瘤：人用医药产品科学评审委员会评估总结
The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Elias Péan, Beatriz Flores, Ian Hudson, Jan Sjöberg, Kristina Dunder, Thomas Salmonson, Christian Gisselbrecht, Edward Laane, Francesco Pignatti
The Oncologist 2013; 18:625-633; first published on April 24, 2013; doi:10.1634/theoncologist.2013-0020

Top of Page

美国食品药品管理局批准概要：厄洛替尼作为一线药物治疗表皮生长因子受体外显子 19 缺失或外显子 21 (L858R)替换突变的转移性非小细胞肺癌
U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations
Sean Khozin, Gideon M. Blumenthal, Xiaoping Jiang, Kun He, Karen Boyd, Anthony Murgo, Robert Justice, Patricia Keegan, Richard Pazdur
The Oncologist 2014; 19:774-779; first published on May 27, 2014; doi:10.1634/theoncologist.2014-0089

肿瘤药物的批准申请：对肿瘤药物咨询委员会审查的分析描述
Applications for Oncologic Drugs: A Descriptive Analysis of the Oncologic Drug Advisory Committee Reviews
John K. Chan, Tuyen K. Kiet, Bradley J. Monk, Nichole Young-Lin, Kevin Blansit, Daniel S. Kapp, Idoroenyi Amanam
The Oncologist 2014; 19:299-304; first published on March 5, 2014; doi:10.1634/theoncologist.2013-0276

批准概要：西妥昔单抗联合顺铂或卡铂和5-氟尿嘧啶一线治疗复发性局部或转移性头颈鳞癌
Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer
Martin H.Cohen, Huanyu Chen, Stacy Shord, Chana Fuchs, Kun He, Hong Zhao, Sharon Sickafuse, Patricia Keegan, Richard Pazdur
The Oncologist 2013; 18:460-466; first published on April 10, 2013; doi:10.1634/theoncologist.2012-0458

肿瘤药物研发与美国食品药品监督管理局批准的全身抗癌药
Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration
Robert E. Martell, David Sermer, Kenneth Getz, Kenneth I. Kaitin
The Oncologist 2013; 18:104-111; first published on December 20, 2012; doi:10.1634/theoncologist.2012-0235

Top of Page

微波消融联合碘-125粒子植入用于局部控制复发性腹膜后脂肪肉瘤的可行性和疗效：初步临床经验
Feasibility and Efficacy of Microwave Ablation Combined with Iodine‐125 Seed Implantation in Local Control of Recurrent Retroperitoneal Liposarcomas: Initial Clinical Experience
Mingjian Lu, Wang Yao, Tao Zhang, Wenzhe Fan, Zhihui Zhong, Jiaping Li, Fujun Zhang
The Oncologist 2017; 22:1500-1505; first published on July 12, 2017; doi:10.1634/theoncologist.2016-0499